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Summary 
 
Radiotherapy (RT) of the breast for early stage breast cancer traditionally requires whole 
breast irradiation followed by a small boost area of treatment to the original tumour bed. 
Accurate localisation of the tumour bed is essential. With the advent of new complex 
treatment strategies and computer tomography (CT) simulated radiotherapy planning there is 
a need to develop an expert localisation procedure that represents best practice. The use of a 
defined surgical clipping program and suitable on-treatment imaging should assist with 
accurate delineation of tumour volumes for radiotherapy to the breast.  
Patients who require chemotherapy prior to radiotherapy pose significant delineation issues 
when using CT without clips. This group experiences a considerable time period between 
surgery and their radiotherapy planning CT and often has complete resolution of the seroma 
by the commencement of treatment, so would most benefit from breast lumpectomy clipping 
at the time of surgery. The clips would allow for localisation and verification of the tumour 
bed in breast lumpectomy patients, regardless of visible seroma. 
At different time points post-surgery the lumpectomy cavity can vary greatly in size and 
shape, so the best time following surgery to delineate the cavity should be established. This 
cavity is delineated by the Radiation Oncologist (RO) at the time of the initial planning CT 
within our institution. If the cavity is clinically deemed too large a second scan may be 
requested and replanning requested. 
This project was designed (1) to examine the feasibility issues of a new procedure for breast 
radiotherapy to improve tumour bed localisation with surgically inserted clips for clinical 
target volume (CTV) delineation, (2) to determine whether the optimal time for the CT 
planning scan can be predicted, and (3) to evaluate the best method for breast imaging on the 
treatment machine. 
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Forty-two (42) individuals with pathologically diagnosed early stage breast cancer who were 
either post-menopausal or over the age of forty years were recruited for this study. These 
patients were split into two study cohorts: those who commenced conservative breast therapy 
with a breast lumpectomy followed by radiotherapy, and those who had breast lumpectomy 
surgery, then chemotherapy (Chemo), followed by radiotherapy. This ethics approved study 
consisted of radio opaque surgical clips being placed around the surgical bed at the time of 
surgery. These clips were then used by the radiation oncologist to ensure consistent CTV 
delineation of the tumour bed. The CTV volume was measured on serial CT data sets taken 
at differing time points post-surgery and during radiotherapy.  
Characterisation of the CTV changes post-surgery and during radiotherapy with or without 
chemotherapy delay demonstrated that the breast boost CTV changed significantly and that 
the initial defined CTV is not a predictor of relative CTV reduction. Regardless of the 
addition of chemotherapy, significant volume reductions were demonstrated in both groups 
of patients, with a 38.4% reduction at median 9 weeks for the RT group and 43.6% reduction 
at median 19 weeks for the Chemo/RT group (see Table 3.2 page 49). Commencement of 
treatment by no later than 9 weeks post-surgery is recommended based on both reported 
primary literature and from our observations of slowing seroma reduction over time. Thus 
due to planning time frame constraints, planning CT scans should be completed between 6-7 
weeks after surgery, which would allow treatment to commence within the next several 
weeks. After 19 weeks, very little extra volume reduction was seen in the Chemo/RT cohort, 
with a mean CTV of 3.6 cc at 40 Gy (Table 3.2 page 49). There is therefore no need for an 
additional CT for either cohort to be completed at 40 Gy except for those patients who have 
an initial CTV greater than 50 cm
3
 (Figure 3.5 page 50). CTV reduction correlates to time 
post-surgery and appears to have no relationship to either radiotherapy or chemotherapy. 
In study three a thorough literature review was carried out into on board kV imaging (OBI) 
for breast radiotherapy. Recommendations about routine on treatment verification imaging 
are based on the following factors: the purpose for kilovoltage (kV) imaging, collision risks, 
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image quality/contrast, radiation dose, accurate registration methods, and marker based 
matching and CTV monitoring. For robust radiotherapy techniques such as the traditional 
two field tangential technique, megavoltage (MV) imaging with current CTV-PTV margins 
of 10mm is adequate. When implementing complex radiotherapy breast treatment techniques 
such as Intensity Modulated Radiotherapy (IMRT), Accelerated Partial Breast Irradiation 
(APBI), Sequential Integrated Boost (SIB) and sequential photon beam boosts, to 
accommodate changing target volumes, volumetric kV CBCT becomes more important. 
The work carried out for this thesis has informed practice in the following areas: routine 
insertion of surgical clips at the time of lumpectomy, characterisation of change of CTV over 
time leading to recommendations regarding the optimum time to carry out pre-treatment CT, 
and recommendations regarding routine on-treatment verification imaging. 
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Introduction 
Significance 
The advent of computer tomography (CT) simulated radiotherapy planning for breast cancer 
has allowed the development of an expert clinical target volume (CTV) localisation 
procedure that represents best practice (Hansen et al., 2012; Wang, French, & Boyages, 
2012). A defined surgical bed clipping program will assist with the accurate delineation of 
tumour volumes for radiotherapy to the breast (Weed et al., 2004), but to date there has been 
no published Australian institutional study describing such a protocol.  
The identification of breast boost volume changes over time using a standardised clip CTV 
delineation protocol has also not been investigated in an Australian patient population. 
Moreover, there is limited published data available on the relationship between time from 
surgery and the size of the CTV. Thus, before embarking on new radiotherapy treatment 
techniques such as SIB, APBI, IMRT or ART, the issues of CTV delineation and how these 
volumes change from surgery to the completion of radiotherapy should be explored. 
The use of image guided radiotherapy (IGRT) enables real time treatment verification, 
which is the final step in ensuring consistent accurate treatment delivery for radiotherapy 
patients. A growing number of recent studies have shown that it is possible to use IGRT to 
improve treatment delivery for complex radiotherapy treatment (Coles et al., 2007; 
Topolnjak et al., 2010a; White et al., 2007). This thesis explores this issue in the context of 
utilising commercially available kV On Board Imaging (OBI) systems both in the 2D and 
3D setting. A particular focus will be the use of imaging to match to surgically placed radio 
opaque clips in preparation to initiate a kV OBI verification protocol for photon boost 
treatments. 
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Structure 
The thesis is arranged into five chapters. Chapter One is an overview of the thesis and 
provides the background literature relevant to the context of breast radiotherapy.  
This thesis covers three research projects, described in Chapters Two, Three and Four, that 
can each be read independently. Each project has an introduction, method, results and 
conclusion, and the intention is to submit them all for publication after submission of the 
thesis.  
Chapter Two describes the design and implementation of a radiation-therapist led trial to 
develop a protocol for insertion of surgical clips into the breast surgical bed.  
Chapter Three presents a prospective research study analysing CTV changes over time. It is 
an investigation into the relationship between time after surgery and seroma size, using a 
comparison between radiotherapy alone patients and patients having radiotherapy delayed 
due to post-surgical chemotherapy.  
Chapter Four is an analysis of the on-treatment imaging options for localisation of the breast 
CTV, using a systematic review of the published literature.  
Chapter Five is an overall discussion of the project as a whole. 
The appendix at the end of the thesis provides supplementary material related to study 
design, including relevant institutional ethical approval statements and protocol development 
documents. 
Aims  
1) To develop expert standards of practice in breast tumour localisation utilising surgical 
clips. 
2) To inform clinicians of the best time to CT plan patients in terms of stable breast boost 
clinical target volumes (CTVs), by evaluating the rate and extent of CTV shrinkage for those 
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undergoing radiotherapy alone as well as those having radiotherapy delayed due to 
chemotherapy. 
. 
3) To analyse on board treatment kilovoltage (kV) imaging to verify complex breast 
radiotherapy treatments. 
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CHAPTER 1  
Background and Literature Review 
1.1  Incidence and treatment of breast cancer 
Breast cancer is the most common cancer among Australian women, accounting for 27% of 
all cancer diagnoses in 2007. Eighty eight per cent of women in Australia who are diagnosed 
with breast cancer live beyond 5 years (AIHW, 2010).  In NSW, breast cancer accounts for 
28% of new cancers and 16% of female cancers (Tracey, Kerr, Dobrovic, & Currow, 2010). 
On average, one in eight Australian females will develop breast cancer and one in 37 
females will die from it before the age of 85 years. More than 69% of breast cancers were 
diagnosed in those aged 40–69 years in 2011. The management of breast cancer is therefore 
an important topic for the Australian health system (AIHW, 2012). 
Breasts consist mainly of fat and glandular tissue arranged in lobules which in women of 
child bearing age can produce milk. Their weight and dimensions differ at different periods 
of life, and in different individuals. The deep surface of each is nearly circular, flattened, or 
slightly concave, and has its long diameter directed upward and lateral toward the axilla. It is 
separated from the fascia covering the pectoralis major, serratus anterior, and obliquus 
externus abdominis muscles by loose connective tissue. The breast has 15 to 20 sections that 
are called lobes which have smaller sections called lobules where milk is produced. The 
lobes and lobules are all linked by small tubes called ducts. The nipple and areola are 
situated on the surface of the breast at the end of these ducts (Standrig, 2005). Figure 1.1 
depicts the anatomy of the breast. 
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Figure 1.1 Anatomy of the female breast 
 Source: National Cancer Institute, 2009. (AIHW, 2009) 
Breast lumps can be either benign in nature or have the potential to invade surrounding 
tissues. In the majority of invasive breast cancers, the abnormal cell growth begins in the 
ducts; this type of breast cancer is referred to as infiltrating (or invasive) ductal carcinoma. 
Invasive lobular carcinoma is another type of invasive breast cancer which begins in the 
lobules. Other, less common types of breast cancers include inflammatory breast cancer, 
medullary carcinoma and Paget’s disease. In Australia in 2008, more than three-quarters of 
breast cancer in females were classified as invasive ductal carcinoma (AIHW, 2012). There 
are two non-invasive forms of breast cancer that, if they remain untreated, have a high 
chance of subsequently becoming invasive breast cancer. These are ductal carcinoma in situ 
(DCIS), a non-invasive carcinoma which is contained in the milk ducts at diagnosis, and 
lobular carcinoma in situ (LCIS) in the lobules. Women diagnosed with DCIS have about a 
10 per cent chance of being diagnosed with a subsequent invasive breast cancer within 10 
years. Breast cancer is categorized as Stage I, II (A or B), III (A, B, or C), or IV. The stage is 
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based on the size of the tumour and whether the cancer has spread. Stages I, IIA, IIB, and 
IIIA are considered "early-stage" breast cancer and refer to cancers that may have spread to 
nearby lymph nodes but not too distant parts of the body (U.S. Department of Health, 2012).  
Therapeutic options for breast cancer depend on several factors including the size of the 
tumour, its location, the tumour type, the risk of spread and the overall health status of the 
patient. The treatment of early stage breast cancer can consist of surgery, chemotherapy, 
radiotherapy, hormonal therapy and specific target drugs. Some of these will be used in 
isolation but most in combination, depending on the disease type and stage. The removal of 
the cancer by surgery is the primary means of treatment for early stage breast cancer, either 
as total mastectomy or wide local excision, which is usually followed by radiotherapy. For 
those patients with slightly more aggressive features where the risk of regional or systemic 
spread are high, the sequence of treatment will be surgery, followed by chemotherapy, and 
then radiotherapy  (Edward, C.  Perez, C & Brady, L. 2008). 
1.2  Radiotherapy of the breast 
The main aim of external beam radiotherapy (EBRT) for early stage breast cancer is to 
destroy any cancer cells that may remain in the breast and surrounding area after surgery, 
while chemotherapy is used to prevent spread to other anatomical sites outside the breast. 
Historically, a total mastectomy was carried out for patients who had small breast tumours. 
However, breast conserving therapy (BCT), which consists of a lumpectomy followed by 
breast irradiation, produces survival results similar to mastectomy. A meta-analysis by the 
Early Breast Cancer Trialist Group confirmed that both mastectomy and radiotherapy 
following lumpectomy reduce the 5-year local recurrence rate from 26 to 7% (Clarke et al., 
2005). Poortmans et al. (2008), using 10 year randomized data from over 5000 patients, 
demonstrated the effects of the addition of a 16 Gy boost dose to the primary tumour site 
following BCT, and reported improved local control. Whole breast irradiation (WBI) 
generally consists of a simple two field tangential field arrangement followed by a direct 
electron field called the boost that is delivered to the primary tumour site. 
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In a meta-analysis of 17 randomised trials, radiation delivered after breast conservation 
surgery was shown to reduce mortality by 3.3% in node negative patients and 8.5% in 
patients with node positive disease (Buchholz. 2011). Veronesi et al. (2002) published 20 
year follow results of a randomised study comparing the efficacy of radical mastectomy 
(n=349) with breast conserving surgery followed by radiotherapy (n=352). For those patients 
with relatively small breast cancers there was the same long term results of those who 
undergo radical mastectomy,  
The area of highest risk of recurrence is the region closest to the primary tumour site (Clark 
et al., 1996; Fisher et al., 2002; Veronesi et al., 2001). Romestaing et al. (1997) reported 
reduced recurrence rates with no decrease in cosmetic outcome after 50 Gy was delivered to 
the whole breast followed by a 10 Gy boost to the primary tumour site, compared to earlier 
dosing regimens with no boost. Bartelink et al. (2007), moreover, in a 10-year study of 5,318 
patients, the randomised boost versus no boost EORTC 22881-10882 trial, 50 Gy was 
delivered to the whole breast with stratification to either no boost or a 16 Gy boost delivered 
to the primary site. After a median follow up of 10.8 yrs the 16 Gy boost improved overall 
regional control for all age groups, however demonstrated no overall survival difference. 
Therefore, good quality irradiation and particularly tumour bed boost irradiation prevent 
local tumour recurrence. EviQ Online version 1.4.0. (Cancer Institute NSW, 2013) has 
collated this information into an online evidence based resource for radiation oncology 
providers to ensure that they are using up to date evidence based treatments and practices for 
all cancer sites 
Technical excellence is an important factor in the delivery of all forms of radiotherapy. The 
importance of expert technical delivery of RT for cancer was demonstrated in a large 
international phase III trial (n=589) the TROG 02.02 head and neck study by Peters et al. 
(2010). In this landmark Australian driven study inferior radiotherapy resulted in a 24% 
reduction in loco regional control and a 20% reduction in overall survival at 2 years. Abe et 
al. (2005), in a meta-analysis of randomized trials that began in 1995 assessing local 
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regional control and mortality of breast cancer patients, showed that the technical quality of 
radiotherapy delivered is also important for breast cancer patients.  
 
1.3  Current advancements in breast radiotherapy 
The simple whole breast tangential beam technique has the potential to induce contra lateral 
breast tumours and cardiac and lung toxicity (Borger et al., 2007; Harris et al., 2006). New 
technologies and techniques for the improved delivery of early stage breast radiotherapy 
aiming to reduce these toxicities have appeared in the last few years: currently there are a 
number of these under investigation in phase III trials throughout the world (Danish Breast 
Cancer Cooperative Group, 2009 ; Wolmark & Curran 2007; Yarnold & Coles, 2009). 
Intensity Modulated Radiotherapy (IMRT) and on-treatment imaging have provided 
opportunities to deliver EBRT to both the whole breast and tumour bed using techniques that 
reduce treatment fractionation and irradiated volume (Hurkmans et al., 2012; Offersen, 
Overgaard, Kroman, & Overgaard, 2009). 
IMRT has been shown to improve dose homogeneity and volume conformity for breast 
radiotherapy (Harsolia et al., 2007; Johansen, Cozzi, & Olsen, 2009; Mell, Mehrotra, & 
Mundt, 2005). Conventionally, the boost irradiation was planned and delivered after 
completion of whole breast irradiation. However, it is now possible to treat the whole breast 
volume and boost volume simultaneously. The simultaneous integrated boost (SIB), which 
incorporates simultaneous delivery of the boost, is in some departments throughout the 
world replacing the older sequential electron boost technique. IMRT SIB not only improves 
dose homogeneity, but also decreases the number of treatment fractions. (Hurkmans, Meijer, 
van Vliet-Vroegindeweij, van der Sangen, & Cassee, 2006; Mayo, Lo, Fitzgerald, & Urie, 
2004; McDonald, Godette, Whitaker, Davis, & Johnstone, 2010). IMRT SIB has provided 
more conformal plans than conventional sequential boost planning (Hurkmans et al., 2006). 
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This conformity, however, can be lost over the course of treatment if there are changes in the 
boost clinical target volume (CTV). This issue will be discussed in chapter 3. 
 
If recurrence most commonly occurs close to the tumour bed, a long course of radiotherapy 
to the whole breast does not seem necessary (Boyages et al., 1990; Swanson & Vicini, 
2008). There have been moves to decrease the amount of breast tissue irradiated, by only 
irradiating the post-surgical cavity with a margin of adjacent breast tissue. This partial breast 
irradiation (PBI) technique is administered either as EBRT or delivered as interstitial 
brachytherapy. In accelerated partial breast irradiation (APBI) the dose is delivered in a 
hypo-fractionated treatment scheme to small tumour bed volumes plus a margin of healthy 
tissue. There has been growing interest in APBI and various approaches to this which  have 
been developed and are undergoing phase I-III clinical studies (Mannino & Yarnold, 2009).  
Polgár et al., (2004) reported after 7 years on a prospective study of accelerated partial breast 
irradiation (APBI) using interstitial high-dose-rate brachytherapy. The results were 
compared with those achieved by standard, whole breast radiotherapy (WBRT), with or 
without a tumour bed boost and recurrence rates equivalent to those of whole breast 
irradiation followed by boost were reported. Since its introduction, APBI has been under 
continuous debate regarding its efficacy, and results are pending for many of the clinical 
trials. Regardless of the lack of results, many institutions have implemented this technique. 
The American Society of Radiation Oncology (ASTRO) has published consensus guidelines 
to help with its implementation (Smith et al., 2009). Some issues relating to the 
implementation of this technique are patient selection in terms of histopathology, tumour 
margins and risk of recurrence. An important aspect of APBI is ensuring accurate CTV 
delineation. Kirby et al. (2010) in a review of published literature on CTV delineation for 
complex treatment techniques such as APBI stressed the importance of accurate definition of 
the CTV. APBI involves irradiating a small, potentially mobile breast CTV, so if a small 
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CTV changes across the radiotherapy treatment course, relatively major target localisation 
errors could occur. 
Another new technological advancement to improve breast radiotherapy and to reduce heart 
and lung toxicity is deep inspiration breath hold (Korreman, Pedersen, Nøttrup, Specht, & 
Nyström, 2005; Remouchamps et al., 2003; Stranzl & Zurl, 2008; Wang, Purdie, et al., 
2012). Treatment is delivered in a breath hold position where the heart becomes displaced 
posteriorly by the inflation of the lungs and thus the amount of irradiated heart and lung is 
reduced. This is not the topic of this thesis, so will not be discussed further. 
1.4 Contouring CTVs for breast radiotherapy  
Whole breast irradiation (WBI) plus a boost, PBI, and SIB all require CTV delineation. The 
boost CTV for breast cancer is located at the site from which the tumour has been removed 
(tumour bed) and this volume of tissue requires a tumouricidal dose. Historically, the tumour 
bed and thus the breast boost CTV of breast radiotherapy patients has been defined by a 
variety of methods that have included clinical palpation, visualisation of the surgical scar, 
pre surgical imaging such as mammography, ultrasound, or MRI and even patient 
recollections of the tumour site. Even with surgical notes clinical palpation by the Radiation 
Oncologist is a very subjective technique that also requires the patient to remember where 
the tumour was located. The surgical scar has also been used as an indicator of the tumour 
bed, but with modern cosmetic surgeries the scar often bears no relation to the actual tumour 
site (Denham, Sillar, & Clarke, 1991); with Machtay et al. (1994) reporting that boost 
coverage using the scar based approach was inaccurate 20%-88% of the time. Ultrasound 
has also been used to localise the breast boost field and improved on clinical mark up by 20-
50% (Ringash et al., 2004). Poor accuracy in CTV delineation has resulted in under dosing 
of the tumour bed and has increased the dose to normal tissues (Coles & Yarnold, 2010). 
With the introduction of Computer Tomography (CT) there has been an 80% improvement 
in CTV delineation compared to clinically defined boost CTVs (Messer, Kirikuta, 
Bratengeier, & Flentje., 1997). However, there have been many studies indicating that there 
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is inter-observer variability in defining the tumour bed on CT (Landis et al., 2007; Lee et al., 
2012; Li et al., 2009; Petersen et al., 2007; Struikmans et al., 2005). 
Following most wide local excisions, when breast surgical cavity fluid is under pressure the 
interface between fluid and breast tissue defines the tumour bed and is known as a seroma, 
which can be observed on CT. There are a number of problems when using the seroma alone 
to define the boost CTV, which include seroma definition, clinical factors such as infections, 
post-operative complications and changes in surgical techniques. Clearly defined seromas 
are unusual, which leads to inter-observer variability (Landis et al., 2007). Clinical factors 
associated with reduced concordance between CTV delineation were found to include the 
following: tissue stranding from the surgical cavity, proximity to muscle, dense breast 
parenchyma, and benign calcifications that could be mistaken for surgical clips. The largest 
variation in boost CTV delineation occurs in the medio-lateral and cranio- caudal directions 
(Li et al., 2009; Petersen et al., 2007).  
Post-operative complications such as haematomas (Paterson, Nathanson, & Havstad, 1994) 
and infection (Indelicato et al., 2007) add to the difficulties of accurate CTV delineation. 
The open closure surgical technique is a method where a large incision is made, diseased 
tissue is removed, and the wound is closed, resulting in a fluid-filled cavity, and has been 
routinely used for breast conserving surgery. Even with drains inserted to remove excess 
surgical fluid, a large seroma can result, which can lead to post-operative complications. A 
newer technique, full thickness closure, involves close apposition and suturing of the walls 
of the cavity. This reduces post-operative infection and results in better cosmesis (Mukesh et 
al., 2012). Full thickness closure does not result in large seromas. More patients are now 
undergoing oncoplastic surgery and/ or breast reductions at the time of removal of the 
primary tumour. These surgical procedures often result in distortions of the seroma shape 
and thus are not necessarily a true representation of the location from which the tumour was 
removed. These distortions create difficulties for the Radiation Oncologist (RO) in defining 
the CTV (Kader et al., 2008). Studies of inter-observer variation of the boost volume 
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highlight the need to implement definition guidelines to improve consistency in CTV 
delineation (Landis et al., 2007; Lee et al., 2012; Li et al., 2009; Petersen et al., 2007; 
Struikmans et al., 2005) 
New tools to aid in defining the breast CTV include pre-operative CTs and Magnetic 
Resonance Imaging (MRI). Boersma et al. (2012), in a study of 30 patients, investigated 
whether using a pre-operative CT scan decreases inter observer variation of boost-CTV 
delineation in breast conserving therapy (BCT), and whether the pre- operative CT 
influences the size of the CTV. However, pre-operative CTs are not commonly used and 
have only had modest success in limiting inter observer variability.  MRI, with its high 
resolution sensitivity in breast tissue, offers superior soft tissue definition for CTV 
delineation, but it is difficult to image breast patients’ supine on the MRI couch to simulate 
the treatment position. MRI is also an expensive option for CTV delineation (Whipp, 
Beresford, Sawyer, & Halliwell, 2010; Whipp & Halliwell, 2008). 
The Radiation Therapy Oncology Group (RTOG) Breast Cancer Atlas (White et al., 2013) 
defines a ‘lumpectomy GTV’ which includes the seroma (because gross tumour has been 
removed surgically) and surgical clips when present. A one centimetre margin is then added 
to create the CTV (ICRU, 1999). If local relapse occurs at the foci of the residual disease or 
in the vicinity of the tumour bed after complete microscopic resection, the CTV margin 
logically takes into account the primary tumour position (Vicini, Kestin, & Goldstein. 2004). 
There were no consensus guidelines for CTV definition within the Australian setting when 
this research was instigated in 2010. Wang et al. (2012) in the article entitled, “Put the felt 
pen away: Time to move on from a clinical mark-up for a breast boost”, emphasised the 
need to move towards CTV delineation within Australia using more complex methods such 
as seroma definition and the use of surgical clips. This move towards CTV delineation using 
more complex techniques such as identification of the seroma with clips was the drive 
behind this research in 2010. 
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The term CTV is used in this thesis (based on the departmental breast voluming protocol, 
2010), and is defined as the surgical cavity, seroma and surgical clips as seen on a diagnostic 
quality planning CT. The CTV is then expanded by a fixed margin to create the planning 
target volume (PTV).The term tumour bed plus a small margin can also be used to describe a 
breast CTV and is often used when describing CTVs where no seromas are present. Authors 
often use the terms surgical cavity, excision cavity, seroma and tumour bed interchangeably 
in literature, but all describe the primary site from which the tumour has been removed 
during surgery. The following figures depict the boost CTV delineation using surgical radio 
opaque clips at the Northern Sydney Cancer Centre (see Figures 1.2 and 1.3). 
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Figure 1.2 Transverse view of Right Breast with Boost CTV in Green, PTV in Orange 
and Breast PTVeval in Red 
 
Figure 1.3 Sagittal view of Right Breast with Boost CTV in Green, PTV in Orange and 
Breast PTVeval in Red 
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1.5 Surgical clips to aid CTV delineation  
Surgical clips have been used as radio opaque markers to define the depth of the surgical bed 
for some time (Bedwinek, 1993; Harrington et al., 1996). These clips can be seen on CT and 
can therefore be used to delineate the boost CTV. Clips have also been used to define 
tangential beam placement (Krawczyk & Engel, 1999). The value of surgical clips was 
established by Denham et al. (1991) and Harrington et al. (1996), who found that the 
electron boost fields of the early 90s would have inadequately irradiated the CTV up to 68% 
of the time, as the clip placed at depth during surgery showed significant under dosing.  
Surgical clips not only define the depth of the tumour bed, but have the potential to be 
attached to the excision cavity walls. These clips, used in conjunction with CT, help the 
delineation of the CTV. Weed et al. (2004) demonstrated on 28 patients that clips are a 
strong radiographic surrogate for the excision cavity and that, due to this improved accuracy 
of definition, the planning target volume (PTV) margin could potentially be reduced safely 
from 1 cm to 5mm. Larger randomised studies would be required before margin reduction 
would be recommended for this population of patients. Based on an analysis of seven peer 
reviewed articles utilising clips Kirby et al. (2010) when describing the current approaches 
of CTV delineation for PBI, recommended tumour bed delineation using CT and implanted 
excision cavity wall markers for the purpose of external beam radiotherapy and or partial 
breast irradiation. These clips are inexpensive to use and are recommended in UK surgical 
guidelines to ensure consistent CTV delineation (BASO 2009) and for specific clinical trials 
(Coles et al., 2009).  
The optimal number of clips to be used has been under investigation for a number of years. 
Goldberg et al. (2005) used a single chest wall clip as visualised on CT as the surrogate for 
the tumour bed, while Kirova et al. (2010) suggested at least 3 or more clips to improve 
tumour bed delineation. However more recent researchers (Coles et al., 2009; Coles et al., 
2007) have suggested that 6 clips should be placed radially around the tumour, which would 
enable more accurate CTV delineation. Kokubo et al. (2001) looked at the impact on local 
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control of boost irradiation 42 months post treatment with 4 surgically placed clips. They 
found a significant advantage for local recurrence free survival of 97% for those with clip 
localisation compared to 88% with no clip boost localisation. The possibility of clip 
migration has been suggested as the reason for the slow uptake of this method of CTV 
delineation but Coles and others (2009) successfully implemented a localisation clipping 
program for 30 patients as part of the UK IMPORT (Intensity Modulated Partial Organ 
Radiotherapy) trial and demonstrated no clip migration. 
1.6 The timing of radiotherapy post-surgery 
Radiotherapy is usually given following surgery but if chemotherapy is recommended, 
radiotherapy will commence soon after chemotherapy has been delivered. Researchers 
suggest that there should be limited time delay from surgery to treatment, either radiotherapy 
or chemotherapy, to inhibit progression of the disease and enhance cure rates (Chen, King, 
Pearcey, Kerba, & Mackillop, 2008; Hébert-Croteau, Freeman, Latreille, Rivard, & Brisson, 
2004; Huang, Barbera, Brouwers, Browman, & Mackillop, 2003; Slotman, Meyer, Njo, & 
Karim, 1994). Stefoski et al. (2004) reported that surgery to radiotherapy intervals of greater 
than 9 weeks had a trend towards an increased relative risk of death. 
Patients who require chemotherapy prior to radiotherapy experience considerable delays 
from surgery to their pre-radiotherapy planning CT and often have complete resolution of 
the seroma by the commencement of treatment (Kader et al., 2008). This issue will be 
discussed in chapters 2 and 3. Radio opaque surgical clips would allow for localisation and 
verification of the CTV of the breast lumpectomy patients regardless of seroma visualisation 
(Coles et al., 2009; Smith et al., 2009). 
1.7 Dynamic CTVs 
Radiotherapy depends upon accurate delineation of the CTV. Systematic errors can be 
introduced at the preparation stage of treatment or at any time throughout the treatment 
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course (Van Herk, 2004). Organ delineation uncertainty is one example of a systematic error 
that is initiated at the beginning of a course of radiotherapy. 
The contour of the breast CTV at the time of planning is usually considered to be 
representative of the CTV during the full course of radiotherapy. Generally, once surgery 
has been completed, a planning CT is taken with or without surgical clips as guidance. These 
scans may be taken as little as three weeks post-surgery, when the healing process is far 
from complete and the tissue remodelling may still be occurring as part of this process. As 
the planning CT is a “snap shot in time” of the size and shape of the breast tissue, any 
changes in the CTV from surgery to the completion of radiotherapy have the potential to 
lead to over or under dosing of healthy tissue. In clinical practice, the time interval between 
surgery and treatment planning and even the experience of the radiation oncologists (ROs) 
may hinder accurate CTV delineation (Kader et al., 2008; Weed et al., 2004; Wong et al., 
2006). These inconsistencies in CTV delineation have the potential to create large systematic 
errors.  
Many authors have demonstrated that the lumpectomy cavity, and thus ultimately the CTV, 
change significantly over a course of treatment (Jacobson, Betts, & Smith, 2006; Kader et 
al., 2008; Kim, DeCesare, Vicini, & Yan; Oh, Kong, Griffith, Yanke, & Pierce, 2006; 
Tersteeg, Roesink, Albregts, Wárlám-Rodenhuis, & van Asselen, 2009; Weed et al., 2004). 
Kim et al. (2008), in a meta-analysis of the work of four groups, plotted mean cavity volume 
versus mean days from surgery and demonstrated that there was an initial increase in cavity 
volume at approximately two weeks followed by considerable shrinkage. Most cavity 
reduction was found to occur when the initial CT scan had been acquired at 2-4 weeks post-
surgery. Since the aim is to treat as little healthy tissue as possible, radiotherapy planning 
images should be taken when the CTV is at its smallest to avoid over-dosage and potential 
future re planning. Planning should therefore be completed when the CTV is at its most 
stable.  
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No Australian consensus guidelines exist describing when the best time to CT plan for the 
breast boost. In the department where this research was carried out in 2010, the planning CT, 
on which the boost CTV is delineated, was acquired approximately 2-3 weeks after surgery. 
This worked well when the boost CTV did not greatly change size and shape over time. Part 
of the department’s radiotherapy protocol in 2010 was to rescan for the boost if the CTV 
was considered too large (> 30 cm
3
 volume, based on local clinical experience), or to have 
changed dramatically during treatment, A second scan was then acquired during 
radiotherapy for the purpose of breast boost planning. This second scan would then be used 
to re-plan the patient’s remaining course of treatment, in a simple form of adaptive radiation 
therapy (ART). ART is a closed-loop radiation treatment process where the treatment plan 
can be modified using systematic feedback of measurements. Adaptive radiation therapy 
improves radiation treatment by systematically monitoring treatment variations and 
incorporating them to re-optimize the treatment plan early on during the course of treatment. 
In this process, field margins and treatment doses can be routinely customized to each 
individual patient to achieve more precise targeting. This, in turn, can lead to dose 
escalation, as irradiation of healthy tissue is kept to a minimum (Yan, Vicini, Wong, & 
Martinez, 1997). Alderstien et al. (2011) analysed three different boost radiotherapy 
planning techniques by scanning patients at one week before RT and in the third and fifth 
weeks of RT. For each patient, three plans were generated: (1) sequential whole breast 
irradiation planned on the initial CT, followed by sequential boost planned on the week 5 
CT; (2) SIB: planned on the initial CT; (3) SIB adaptive radiation therapy (SIB-ART): 
planned on the initial CT and re-planned on the week 3 CT. They demonstrated a dosimetric 
advantage for patients with changing seroma sizes when SIB-ART was used with re-
planning halfway through treatment. Hurkmans et al. (2012) also reported on an ART 
protocol where the initial planning CT and lumpectomy were carried out less than 30 days 
post-surgery and patients who had an initial seroma volume >30 cm 
3
 were rescanned at day 
10 of treatment. This protocol for IMRT SIB led to a clinically significant reduction of the 
high dose volumes within the treatment plans. 
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Breast CTV delineation using a conventional CT data set requires the patient to return to the 
CT scanner for tumour volume monitoring or for re-planning purposes. This means that for 
most busy clinical practices an additional planning CT scan can only be performed once 
during a course of treatment. However, Yang et al. (2010) have demonstrated that 
kilovoltage (kV) cone beam CT (CBCT) could be used daily to monitor seroma volume 
changes. This concept is discussed as part of a systematic review in chapter 4. 
1.8 Treatment verification studies: kV imaging and surgical clips 
Accurate treatment delivery is important to achieve the prescribed dose in radiotherapy, and 
improved treatment targeting might facilitate dose escalation. Dose escalation and 
fractionation regimes have increased the probability of tumour control for many tumour sites 
such as prostate and breast. For prostate cancer, Zelefsky et al. (1998), as part of a phase I 
study, safely increased the tumour target dose from 64.8 to 81 Gy in increments of 5.4 Gy. 
Pollack et al. (2000) between 1993 and 1998 investigated the effect on disease free survival 
on 305 stage T1 through T3 patients who were randomized to receive 70 Gy or 78 Gy of 
external-beam radiotherapy and indicated that 70 Gy or more should be given to the prostate 
to ensure disease free survival. For early stage breast cancer patients as previously discussed, 
increasing the boost from 10 Gy to 16 Gy is required to minimise recurrence (Bartelink et 
al., 2007). Liao et al. (2000) also demonstrated, when increasing dose from 60 Gy to 66 Gy 
and comparing different fractionation schedules, that twice-daily post mastectomy radiation 
to a total of 66 Gy for patients with inflammatory breast cancer resulted in improved loco 
regional control, disease free survival, and overall survival. However, dose escalation does 
carry a risk of greater adverse side effects unless the irradiated volume is kept to a minimum 
and targeting of this volume is accurate.  
There are three types of correction protocols generally used for radiotherapy to ensure 
accurate treatment delivery: offline corrections, online corrections and intra-fraction 
corrections (van Herk, 2007). All these corrections require verification imaging on the 
treatment machine. For traditional external beam breast radiotherapy using two tangential 
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beams, online electronic Mega voltage (MV) portal images (EPIs) that are compared to 
digitally reconstructed radiographs (DRRs) were sufficient (van der Laan, Hurkmans, Kuten, 
Westenberg, & Breast, 2010). However for complex treatments such as IMRT and those 
requiring 3 dimensional (3D) internal anatomy visualisation and monitoring, such as APBI 
and SIB, online kilovoltage (kV) imaging is replacing EPIs as the imager of choice for 
Image Guided Radiotherapy (IGRT) (Topolnjak et al., 2010). 
The implementation of new techniques such as APBI and SIB has been slow, partly due to 
the mobile structure of the breast and the need for accurate treatment localisation. Factors 
implicated in CTV mobility in the breast, as in any other region of the body, include patient 
stability, positioning, breathing motion, and contour changes. Immobilisation of the patient 
is an important factor in ensuring accurate treatment and has been investigated by several 
authors (Mitine, Dutreix, & Van der Schueren, 1991; Thilmann et al., 1998). The method of 
breast patient immobilisation used for the patients in this study is discussed in chapter 2.  
There is a range of image guidance methods available, as is discussed in Chapter 4, 
consisting of orthogonal planar imaging, both MV and kV, and volumetric imaging via kV 
cone beam CT (CBCT) and MV systems. MV CBCT is used on helical tomotherapy 
treatment systems. The helical tomotherapy unit itself is essentially a hybrid between a 
linear accelerator and a helical CT scanner for the purpose of delivering IMRT (Welsh et al., 
2002). Tomotherapy has not been considered in this thesis as it is an expensive treatment 
option and is not readily available in Australia. IGRT allows online matching and treatment 
adjustments to be made and anatomy changes to be monitored on a daily basis. Jain et al. 
(2009) used CBCT to measure patient movements during treatment and reported similar 
results to those of EPIs. A comparative study comparing EPIs to CBCT found that EPIs 
underestimate CBCT set up error using bony landmarks for breast cancer patients 20-50% of 
the time. 
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The quality of the 2D or 3D kV images has a major impact on the ability to visualise either 
soft tissues such as the breast seroma, bony anatomy or radio opaque materials such as 
surgical clips. Orthogonal 2D kV images allow isocentre verification. 3D images such as 
those produced by kV CBCT enable internal structures and external patient contours to be 
visualised. The ability to identify internal structures while the patient is in the treatment 
position enables tumour bed tracking, with or without the presence of surgical clips (Weed et 
al., 2004; Z. Yang et al., 2010). Kim et al. (2007) demonstrated the ability to automatically 
track clips in the CBCT image using in house software, making possible the reduction of 
CTV-PTV treatment margins. Also Penninkhof et al. (2009) for a cohort of 30 patients 
showed that surgical clips were relatively stable during radiotherapy treatment and can be 
used as a radiotherapy surrogate for the tumour bed in set up and verification  protocols. The 
use of kV imaging for breast radiotherapy is discussed in depth as part of a systematic 
review in chapter 5. This systematic review will facilitate evidence based practice decisions 
to be made on the use of kV imaging for breast radiotherapy within Australia. 
The three studies that follow describe investigations into localisation of the surgical tumour 
bed using surgical clips to aid in pre-radiotherapy visualisation, the relationship between 
time post-surgery and CTV shrinkage before and during radiotherapy, and an analysis of the 
imaging options for on-treatment verification of the location of the CTV. The results of these 
studies should support improved breast cancer radiotherapy protocols. 
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CHAPTER 2.  
The Successful Implementation of a Multidisciplinary Clip-
Based Protocol for Boost Radiotherapy in Breast Cancer 
2.1 Introduction 
Radiotherapy after breast conserving surgery (BCS) of patients with breast cancer is 
effective in reducing the risk of local recurrence. In a meta-analysis by the Early Breast 
Cancer Trialist Collaborative Group (EBCTCG) it was confirmed that both mastectomy and 
radiotherapy following lumpectomy reduce the 5-year local recurrence rate from 26 to 7% 
(Clarke et al., 2005). Over the last 20 years, breast conservation surgery followed by whole 
breast radiation has been considered standard of care for early stage breast cancer and is 
used in Australia as part of evidence based practice (Veronesi et al., 2002; Cancer Institute 
NSW.,2013). The area of highest risk of recurrence is the region closest to the primary 
tumour site (Clark et al., 1996; Fisher et al., 2002; Veronesi et al., 2001). For patients with 
early breast cancer who undergo breast-conserving surgery and receive 50 Gy of radiation to 
the whole breast, an additional dose of 10-16 Gy to the tumour bed reduces the risk of local 
recurrence, especially in those younger than 50 years of age (Bartelink et al., 2007). 
Accurate tumour bed localisation for radiotherapy facilitates optimum CTV by defining 
tissue at risk of recurrence, ensuring adequate tumour dose (ICRU, 1999). 
Historically, a combination of pre–operative imaging (mammograms), histopathology 
review, surgical scar location and palpation have aided identification of the tumour bed to 
create the clinical target volume (CTV), but there are limitations with all these techniques 
(Denham et al., 1991). The advent of CT simulated radiotherapy planning enabled internal 
structures and the boost CTVs to be delineated. Authors described the use of CT to improve 
the delineation of the breast boost CTV over clinically based techniques (Bedwinek, 1993; 
Benda et al., 2003). Radiotherapy planning localisation has relied on this post-operative 
seroma formation as seen on CT to define the breast CTV. Hansen et al. (2012) compared 
clinical mark up to that defined by the seroma on CT (with or without surgical clips). 
 23 
 
Similarly, Benda et al. (2003) compared clinical mark up with a combination of CT seroma 
and or surgical clip delineation. Both authors concluded that there was improved boost dose 
coverage using a CT based delineation of the boost CTV. However, accurately localising the 
tumour bed to create the CTV on CT can be challenging. If full-thickness closure of the 
excision cavity is performed during surgery a minimal seroma forms making it difficult to 
locate the tumour bed. Dense breast parenchyma can be difficult to interpret on CT and 
researchers have documented inter-observer variability when contouring the postoperative 
seroma (Petersen et al., 2007). Breast surgical techniques have changed so the scar is now 
often placed some distance from the tumour site for better cosmesis, and a UK protocol 
(Coles et al., 2009) recommends that clips be placed at the excision margins prior to tissue 
relocation in order for them to be representative of the original tumour site. 
Kirby et al. (2010) suggested for the purpose of both external beam radiotherapy and partial 
breast irradiation (PBI) that the optimal method of tumour bed delineation requires CT 
imaging with implanted excision cavity wall markers. The practice of accelerated partial 
breast irradiation (APBI) is being investigated in clinical trials in many countries around the 
world; the hypo fractionated dose is delivered to a target volume that is closely related to the 
size and shape of the surgical cavity (Baglan et al., 2003; Smith et al., 2009). Although 
irradiating a reduced volume, recurrence rates for APBI are equivalent to those of whole 
breast irradiation followed by a boost (Polgár et al., 2004). Due to the smaller CTVs, 
accurate tumour bed delineation is critical when embarking on an APBI protocol, so a 
standardised clipping protocol needs to be used in this circumstance. The placement of radio 
opaque tumour markers (surgical clips) during surgery is now recommended in the UK 2009 
surgical guidelines (Association of Breast Surgery, 2009), however, this procedure has yet to 
be standardised as routine practice within Australia. 
As early as 1993, Bedwinek et al. (1993) demonstrated that the skin incision and surgical 
induration are not reliable landmarks for boost field localization and recommended that the 
surgical cavity should be demarcated with surgical clips. Hunter, McFall, & Hehr. (1996) in 
 24 
 
assessing the radiation field dose coverage using radiographic film of the boost, reported that 
without clips, the boost cavity would not have been dosed adequately 46% of the time. 
Goldberg, Prosnitz, Olson & Marks. (2005), compared CT CTV boost delineation to surgical 
clip delineation and determined that a single clip used as a surrogate for the tumour bed 
underestimates the extent of the tumour. The authors suggested that a combination of both 
CT and surgical clips should be used to improve CTV boost delineation. Coles et al. (2009), 
as part of the UK IMPORT (Intensity Modulated Partial Organ Radiotherapy) trial, audited 
the value of titanium clips for tumour bed localisation following BCS for the purpose of 
breast RT planning, and presented a clip based delineation protocol that used 6 titanium clips 
placed around the tumour bed at the time of BCS. 
The addition of radiopaque surgical clips enables the CTV to be delineated on CT data sets 
even in the absence of a seroma. This is particularly important for a subset of patients who 
have increased time delays post-surgery such as those having adjuvant chemotherapy that 
can take four to six months to complete. The accepted sequencing of treatment for these 
patients is surgery, chemotherapy, then radiotherapy to commence 3-4 weeks after the 
completion of chemotherapy. (Jobsen, van der Palen, Brinkhuis, Ong, & Struikmans, 2012) 
Kader et al. (2008) reported that after after 9- 14 weeks’ post-surgery there is often complete 
resolution of the seroma by the time of treatment CT planning, and that the seroma should 
not be the sole tool used for CTV delineation.  
Although clips aid in the localisation of the tumour bed for CTV delineation they also play 
an important role in radiotherapy treatment and verification, two of the fundamental 
elements for accurate radiotherapy delivery. Kim et al. (2007) compared manually matching 
treatment verification images to chest-wall and skin with matching to surgical clips, and 
concluded that using current CTV-PTV margins a clip-based online setup protocol should be 
used. 
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Serial CT imaging has demonstrated clips to be a stable surrogate for a changing tumour bed 
volume (Weed et al., 2004). There is now a large body of evidence that has demonstrated 
that clips are a good surrogate for the surgical tumour bed. (Goldberg et al., 2005; 
Harrington et al., 1996; Hepel et al., 2009; Oh et al., 2006; Weed et al., 2004). 
In 2010 a multidisciplinary surgical clip based marker localisation protocol was introduced 
and evaluated for patients undergoing radiation therapy for breast cancer at the Northern 
Sydney Cancer Care Centre (NSCC) Department of Radiation Oncology at Royal North 
Shore Hospital (RNSH). The primary aim of this study was to improve tumour bed 
localisation and introduce a standard surgical clip based CTV delineation protocol for breast 
radiotherapy patients. The secondary aim was to assess the acceptability of the protocol by 
members of the multidisciplinary team (MDT). 
2.2 Materials and methods 
The issues that were considered and resolved for the introduction of an implanted surgical 
clip program included: selection of the patient group, the implant equipment, procedure, and 
quality assurance process. 
2.2.1 Patient group 
Ethics approval was gained in June 2010 from the Northern Sydney Health Network HREC 
protocol No: 1003-78M and data was collected between September 2010 and December 
2011. As ligature clips are routinely used as a localisation tool to indicate nodal 
involvement, the consent process for surgical clip placement and its complications was 
considered by the surgeons to be part of the normal consent process for surgery.  
Patients were eligible for this study if they had histologically defined early stage breast 
cancer with T1-T2 staging. Due to recruitment issues, recruitment was ceased after 14 
months, with a final cohort of forty two subjects. Of these patients, 15 were required to have 
chemotherapy prior to radiotherapy (Chemo/RT) and 27 were having radiotherapy alone 
(RT/alone) post-surgery. Patients who have more aggressive disease markers often undergo 
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up to 6 months of chemotherapy. Within our referred population many of these women were 
often excluded on the basis of age or menopausal status. More chemo radiotherapy patients 
were excluded due to aggressive disease markers which required up to six months of 
chemotherapy. The combinations of study exclusion criteria and candidature time limits 
limited the Chemo/RT cohort to 15 study patients. As with any statistical test, even with 
small sample sizes, significance can be reached, suggesting that the effect is large enough to 
be clinically relevant. 
 
A sequential retrospective control group of 25 patients who had chemotherapy prior to 
radiotherapy was also selected.  
2.2.2 Implant equipment and procedure 
An extensive literature review was undertaken to investigate the types of materials that could 
be used as a tumour surrogate. Thomas et al. (2009) and Buehler et al. (2009) identified 
appropriate clips to be placed at the time of surgery that could be used both for tumour 
localisation and treatment verification. Availability, ease of use, visibility on kilovoltage 
(kV) On Board Imaging (OBI) for treatment verification and cost were all important factors 
that were considered when deciding which clips to use (see chapter 5). These clips needed to 
be available to all surgeons across a range of public and private sector hospitals. Medium 
titanium clips in a ligiclip multi-applicator system (EthiconEndo-surgery,LLC) with a clip 
height after closure of 6mm were chosen. 
The clip protocol was developed in consultation with the surgeons performing the procedure 
and the radiation oncologists who would use the clips for localisation. The protocol as 
described by Coles et al (2009) for the UK IMPORT (Intensity Modulated Radiotherapy 
Partial Organ Radiotherapy) trial used 6 paired clips to determine the incidence of clip 
migration and reported clip migration to be less than 10%, so paired clips were not thought 
necessary for this study.  
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Initially, the principal researcher delivered an education package to the two surgeons and 
four radiation oncologists involved in this study. This included several PowerPoint 
presentations describing the literature and importance of utilising clips for breast RT, 
protocol design meetings, surgical localisation documentation procedures and surgical visits. 
The development and practice of delineating the CTV using clips on planning CTs by the 
radiation oncologists (RO’s) was also included. At surgery on the first subject, clips were 
placed with a radiation oncologist and radiation therapist present to ensure protocol 
compliance. For all subjects the plan was to place a minimum of 5 medium titanium clips at 
locations around the tumour bed that included the anterior, medial, lateral, inferior and 
superior extent of the tumour bed, and at the deep posterior base of the cavity, usually fixed 
to the pectoralis fascia.  
2.2.3 Volume delineation and quality assurance 
Subjects had a planning CT taken in the treatment position on a radiotherapy breast board 
using a GE Lightspeed CT with 3 mm slice thickness. Scans were taken to encompass the 
whole breast, extending superiorly to include the supra-clavicular margin and inferiorly the 
entire breast tissue plus 2 cm. The CTV was created using the visible seroma, surgical 
information and surgical clips, with all clips to be encompassed in the CTV. The British 
Columbia Cancer Agency Seroma Clarity Scale (Petersen et al., 2007) was used to evaluate 
the ease of delineating the seroma on the planning CT as if no clips were present. This is a 
numeric scale ranging from 0, no visible seroma, to 5, seroma easily visible, homogenous 
with sharp boundaries. For subjects whose seroma visibility score ranged from 0 -3 
(3=seroma identifiable with minor uncertainties) the clips were considered necessary to 
ensure consistent accurate CTV delineation. Seroma scores of ≥4 were easily identifiable 
without the need for clips; thus the clips were considered to have provided no extra 
information and therefore did not improve delineation of CTV by the radiation oncologist. 
To determine the effect of clips on seroma visualisation, a controlled retrospective study was 
performed. It was not possible to blind reviewers to the clips by removing them from the 
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planning CTs, so a control group of 25 randomly selected patients from the 2009 patient data 
base was selected. These patients had received 3-4 cycles of chemotherapy prior to 
radiotherapy and had no clips placed during surgery. Therefore, when evaluating the benefits 
of the clips, the seroma scores for the retrospective control groups were compared with the 
seroma scores for the clipped chemotherapy patients. If a significant difference was detected 
between the seroma scores of the control group and those of the pre chemo study group, the 
clips would be considered to have influenced the reviewers’ seroma scoring.  
Figures 2a, and 2b are examples of study subjects’ seroma clarity scores. Figure 2a shows a 
very clearly defined seroma with sharp identifiable boundaries. This would have been given 
a seroma score of 5 and the clips would have not been required to produce accurate, 
consistent CTV delineation. In contrast, Figure 2b is representative of a patient who had an 
excessive time delay post-surgery before the start of radiotherapy, with a seroma score of 1. 
In this case there is complete seroma absorption and without clips inserted during surgery 
the CTV would have been very difficult to accurately delineate. One observer scored the 
seromas and a second observer was consulted when uncertainties arose. It was noted when 
the seroma was clearly visible but the clips did not match these borders.  
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Figure 2a Seroma score = 5 easily identifiable, homogenous with sharp boundaries. 
Clips not necessary 
 
Figure 2b Seroma score = 1 scar/shadow. Clips are necessary. 
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2.2.4 Satisfaction survey 
To gauge compliance and acceptability of this new surgical clipping protocol a small open 
ended satisfaction survey was completed at the end of subject recruitment (see Appendix E 
and F). The survey was completed by the surgeons placing the clips at the time of surgery 
and the radiation oncologists utilising the clips to aid in accurate CTV delineation. 
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2.3 Results 
The table below depicts the subject characteristics of the two cohorts of study patients. 
Table 2.1 Subject characteristics 
Subjects RT/Alone 
N=27 
 Chemo/RT 
N=15 
Age at Surgery(years)   
 Mean 59 56 
 Range 41-79 42-72 
Tumour Stage   
 T-1 24 5 
 T-2 3 9 
 T-3 0 1 
N Stage 
 0 
 
24 
 
6 
 1 3 5 
 2 0 0 
 3 0 4 
Pathology Type   
 Infiltrating Ductal 20 15 
 Infiltrating Lobular 2 0 
 Ductal Carcinoma In situ 5 0 
Side   
 Left 12 9 
 Right 15 6 
Days from Surgery to CT1   
 Median 25 18 
 Range 10-37 10-28 
Days from Surgery to CT2   
 Median 68 126 
 Range 51-85 94-187 
Days from Surgery to CT3   
 Median n/a 161 
 Range n/a 137-228 
Seroma Score*    
 0-1 3 4 
 2-3 18# 1# 
 4-5 6 0 
* British Columbia Cancer Agency Seroma Clarity Scale. 
# One patient in each of these groups had no clips placed. 
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2.3.1 Tumour bed localisation 
The clips aided CTV delineation in 14 /15 chemotherapy subjects (93%) and in 20 /27(74%) 
radiotherapy alone patients (see Table 2.2). No statistical comparison of CTV delineation 
between groups could be performed due to the small sample sizes. The seroma scores for the 
chemotherapy study group and the control group, who also had been delayed due to 
chemotherapy, were similar, with no seromas receiving a 4-5 score on the seroma 
visualisation scale. This indicates that the scorer’s seroma rating was unlikely to have been 
influenced by the presence of the clips.  
 
Table 2.2 Seroma Visualisation Score 
Seroma Score* RT/alone 
(%) 
Chemo/RT 
(%) 
No clips control Chemo/RT 
(%) 
0-1 3 (11.1) 4 (26.7) 13 (52) 
2-3 18# (66.7) 11# (73.4) 12 (42) 
4-5 6 (22.7) 0 (0) 0 (0) 
Total 27 (100) 15 (100) 25 (100) 
British Columbia Cancer Agency Seroma Clarity Scale * 
One patient in each of these groups had no clips placed # 
 
Two patients (one from each cohort) who were consented for clip placement had no clips 
identified on CT. Both these patients were consented at the beginning of the study and were 
therefore entered for completeness of data analysis. Of the 42 study subjects, the tumour bed 
could be successfully localised when using the visible seroma (score 4-5) for only 6 subjects. 
These subjects were in the radiotherapy alone cohort. The clips gave additional delineation 
information for the remaining 33 cases (those patients with a score ≤3), including 14/15 of 
the chemotherapy subjects (see Table 2.2). In the absence of seromas (i.e. score 0-1) tumour 
localisation relied totally on the surgical clips. For one subject the clips were visible, but one 
clip was not encompassed by the delineated volume. In this case and with those where the 
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clips were not placed, visible seroma and surgical reports became the predominant guide for 
CTV delineation. 
2.3.2 Satisfaction survey of surgeons and radiation oncologists 
Both surgeons said the procedure was easy to carry out and that they would continue this 
procedure post study. They reported difficulty placing the anterior clip close to the 
superficial skin surface due to concerns of cosmesis and marker palpability, so this clip for 
some patients was not inserted. In all subjects surgeons placed at least 4 clips around the 
tumour bed with the deep clip fixed to the pectoralis fascia. They agreed that the 
implementation process gave them a sound knowledge of the problems experienced by the 
radiation oncologist associated with CTV delineation. Four radiation oncologists completed 
the satisfaction survey. All agreed that prior to the introduction of this protocol there were 
difficulties with breast boost CTV delineation. When asked whether it was easier to 
delineate the volumes in patients who had volume resolution after chemotherapy, three 
agreed and one strongly agreed. All agreed that this protocol was beneficial for CTV 
delineation. 
2.4 Discussion 
In radiotherapy normal tissue toxicity must be kept to a minimum, which for patients with 
breast cancer is particularly important for the heart and lung (Cuzick et al., 1994). As 
recurrences are often close to the tumour bed, accurate localisation of the CTV to ensure 
adequate dose coverage is important. With modern surgical procedures it is no longer 
necessary to rely on the surgical scar as the basis for delineating the CTV for breast 
radiotherapy patients (Bedwinek, 1993; Denham et al., 1991; Kovner et al., 1999; Machtay 
et al., 1994). 
When relying on the seroma alone to define the boost CTV there is uncertainty for the 
radiation oncologist because with time, the seroma becomes re absorbed, and the interface 
between the seroma and breast tissue is difficult to visualise. Due to the long time delays 
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experienced by those patients undergoing chemotherapy prior to irradiation, the seroma is 
often undetectable on CT. Clips therefore aid accurate CTV delineation.  
This study describes the successful implementation of a protocol led breast boost 
localisation procedure utilising surgical clips within the Australian context. In order to 
complete this project in a timely manner data collection was limited to a 14 month period, 
thus small subject numbers were recruited for the Chemo/RT cohort. However, since the 
implementation of this clipping protocol the MDT surgeons now routinely place four to five 
surgical clips during surgery and the radiation oncologist uses these to aid in accurate CTV 
delineation for all early stage breast cancer patients. As well as improving breast boost CTV 
delineation the surgical clips can also be visualised during daily treatment to improve 
accurate treatment delivery, as other authors have demonstrated (Buehler et al., 2009; Kim et 
al., 2007; Thomas et al., 2009) . 
The surgeons clipping these patients and the radiation oncologists using clips to delineate the 
CTV all agreed that the procedure was easy to implement. The clips used were relatively 
inexpensive and are often already used as part of the operating procedure for homeostasis or 
specimen localisation. During the implementation phase, even with an extensive education 
program to the entire MDT team before the commencement of this procedure, two patients 
at the beginning of recruitment failed to be clipped due to operating theatre constraints. 
However, once all stakeholders became familiar with the procedure, the process was adhered 
to. The deletion of the anterior clip from the protocol, due to difficulties in its placement, has 
not limited accurate CTV delineation, as the remaining clips and CT density data provide 
adequate information. 
This study supports the findings of others (Coles et al., 2009; Weed et al., 2004) that surgical 
clips can be used as a radiotherapy surrogate for breast boost localisation and that a protocol 
of this nature can be consistently adhered to. In the context of oncoplastic surgery, clips 
should be placed prior to tissue translocation to ensure they represent the original tumour 
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site. Moreover, if re excision is required, clips should be repositioned at the borders of the 
surgical cavity. CTV delineation is very difficult, and in the absence of any distinguishable 
seroma the clips are an invaluable aid in delineating the CTV. This was particularly evident 
for the post-chemotherapy patients, whose seromas had often completely disappeared by the 
time of radiotherapy planning. 
During the seroma scoring process it was not possible to blind the scorer to the clips due to 
limitations of the planning software. To ensure the clips had not confounded the data, the CT 
images of a retrospective group without clips were tested and the findings indicated that the 
clips had not influenced the seroma scores. In the absence of seromas tumour location relied 
totally on the addition of surgical clips. Some authors have reported that electron boost fields 
would not have been adequately dosed at depth, while others have reported that the boost 
field parameters were modified when using clips (Benda et al., 2003; Coles et al., 2009). It is 
recommended that a study be carried out on this cohort of patients where the clips can be 
blinded, using special software. This could confirm planning target volume coverage to 
confirm the findings of Coles at al. (2009) and Benda et al. (2003).  
The use of On board kV imaging to verify breast treatment is discussed as part of a literature 
review in chapter 5. The addition of surgically implanted clips has facilitated a new breast 
photon boost on treatment verification protocol at the NSCC (Department of Radiation 
Oncology) in March 2013. Non-coplanar kV on treatment verification images are acquired 
for the first 2 boost fractions and the surgically inserted clips are used as tumour surrogates 
for OBI matching. The ease of clip visualisation and shifts measured are currently under 
investigation as a feasibility study for 10 patients. 
2.5 Conclusion 
Medium titanium clips inserted at the time of surgery were accepted by the MDT at RNSH 
as an effective aid to improve the delineation of the breast boost CTV for breast radiotherapy 
patients. This clip based protocol which was introduced for all early stage breast 
 36 
 
radiotherapy patients ensures not only for accurate CTV delineation but for accurate tumour 
bed treatment verification a necessity for all boost treatments and partial breast irradiation 
techniques. This protocol will also enable the NSCC to take part in clinical trials requiring 
accurate breast CTV delineation and verification.  
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CHAPTER 3.  
The Influence of Time on Clinical Target Volumes for Breast 
Cancer Radiotherapy 
3.1 Introduction 
Over the last 20 years breast conservation surgery has largely supplanted whole mastectomy 
for early stage breast cancer treatment. This has taken the form of a surgical lumpectomy 
followed by whole breast irradiation and a boost to the tumour bed as reported in two large 
randomized trials ( Fisher et al., 2002, Bartelink et al., 2007). The benefit of improved local 
control by boosting the tumour bed for early stage breast cancer patients has been well 
documented (Bartelink et al., 2001; Bartelink et al., 2007; Romestaing et al., 1997). Boost 
treatment to the breast using external beam radiotherapy can be delivered either sequentially 
or as a simultaneous integrated boost (SIB) (Hurkmans et al., 2006). In the recently 
developed practice of accelerated partial breast irradiation (APBI) for early stage breast 
cancer, the hypo fractionated dose is delivered to a target volume that is closely related to 
the size and shape of the surgical cavity, producing equivalent recurrence rates to whole 
breast irradiation followed by boost (Baglan et al., 2003; Polgár et al., 2004; Smith et al., 
2009). Tissue at risk of recurrence should be covered by optimum CTVs. In the ICRU 62 
report (ICRU, 1999), the boost CTV is defined by the excision cavity, seroma and surgical 
clips as seen on CT. The CTV is then expanded by a fixed margin to create the planning 
target volume (PTV). As the planning CT is a “snap shot in time” of the size and shape of 
the breast tissue, any change in the breast CTV over time from surgery to the completion of 
radiotherapy has the potential to lead to over or under dosing of healthy tissue. 
In the past the boost CTV was defined by clinical landmarks and the surgical scar, which has 
led to over treatment of uninvolved tissues while at the same time under dosing tissues that 
are at risk of recurrence (Benda et al., 2003; Denham et al., 1991; Machtay et al., 1994).  
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Researchers have investigated whether the CTV could be defined consistently, reporting  
large inter observer variability in the delineation of the tumour bed (Landis et al., 2007; Li et 
al.; Petersen et al., 2007; Struikmans et al., 2005). However, CT has improved localisation 
by as much as 80% (Messer et al., 1997) and researchers have demonstrated improved PTV 
boost coverage using CT-based delineation (Hansen et al., 2012). The use of a CT-scan for 
delineation and treatment planning has led to an increase of the irradiated boost volume by a 
factor of 1.5-1.8 compared to conventional simulator-based plans (Al Uwini et al., 2009).  
One method of defining the CTV that has improved tumour bed voluming (Hepel et al., 
2009; Oh et al., 2006; Weed et al., 2004) is the placement of surgical clips at the edges of the 
cavity at the time of surgery (Bedwinek, 1993; Deniaud-Alexandre et al., 2001; Kirova et al., 
2010; Weed et al., 2004).  Kirova et al. (2008) recommended a multidisciplinary approach to 
tumour bed localisation and Coles et al. (2009) recommend inserting 6 titanium clips at the 
time of surgery to reduce intra and inter observer variability of tumour bed localisation. 
Boersma et al. (2012) also found the delineation of smaller and more consistent CTVs by 
using pre-operative CT’s with clinical guidelines. 
Traditionally within our department a planning CT is acquired before the first fraction of 
radiotherapy, which is used to delineate the boost CTV. This works well when the size and 
shape of the tumour volume does not greatly change over time. A second scan can be 
acquired during radiotherapy if the first boost volume is deemed too large. This second scan 
would then be used to re-plan the patient’s remaining course of treatment, in a simple form 
of adaptive radiotherapy. The use of adaptive radiotherapy planning protocols (ART) is 
under investigation (Hurkmans et al., 2012), and Yang et al. (2010) have suggested that cone 
beam computer tomography (CBCT) might also be useful for monitoring boost volume 
reduction, but as yet this has not been accepted as routine  practice. 
Shrinkage of the boost CTV has been investigated by other researchers (Hurkmans, 
Admiraal, van der Sangen, & Dijkmans, 2009; Kim et al.; Oh et al., 2006; Petersen et al., 
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2007; Prendergast et al., 2009; Prosnitz & Haffty, 2009; Sharma et al., 2009; Tersteeg et al., 
2009). Since the aim of radiotherapy is to treat as little healthy tissue as possible, the images 
used for treatment planning should be taken when the CTV is at its smallest and most stable 
to avoid both over-dosage and potential future replanning. When developing ART protocols 
for SIB techniques, clinicians need to take into account these changing boost CTVs. 
Alderstein et al. (2011) recommended when using a SIB technique, to replan halfway 
through a course of treatment as this adaptive technique produced a dosimetric advantage for 
patients with large seromas.  
When relying on the seroma alone to define the boost CTV there is uncertainty on the part of 
the radiation oncologist. Over time, the interface between seroma and breast tissue is 
difficult to visualise as the seroma becomes re-absorbed. This is of particular importance 
when patients are undergoing chemotherapy prior to irradiation, due to the longer time frame 
to treatment. A clip based CTV delineation program is a necessity for these patients to 
ensure consistent CTV delineation. Strauss et al. (2010), discovered that those patients who 
had chemotherapy prior to radiotherapy had smaller boost volumes treated than those having 
radiotherapy after surgery.  
Within our institution, before introducing complex APBI and SIB techniques utilising clip 
based CTV, we felt it was important to investigate boost CTV changes from surgery to the 
completion of radiotherapy. The aim of this study was to establish the best time to CT plan 
patients in terms of stable CTVs for those undergoing radiotherapy alone as well as those 
having radiotherapy delayed due to chemotherapy.  
3.2 Methods and materials  
3.2.1 Patient group 
This ethics board approved study (Northern Sydney Health Network HREC protocol 
No:1003-78M) recruited 42 women who received treatment between September 2010 and 
December 2011. Participants were eligible if they had histologically defined early stage 
 40 
 
breast cancer with T1-T2 staging and were post- menopausal or over 40 years of age. Due to 
recruitment issues, recruitment was ceased after 14 months, with a final cohort of forty two 
subjects. Of these patients, 15 were required to have chemotherapy prior to radiotherapy 
(Chemo/RT) and 27 were having radiotherapy alone (RT/alone) post-surgery. Patients who 
have more aggressive disease markers often undergo up to 6 months of chemotherapy. 
Within our referred population many of these women were often excluded on the basis of 
age or menopausal status. The combinations of study exclusion criteria and candidature time 
limits limited the Chemo/RT cohort to 15 study patients. As with any statistical test even 
with small sample sizes, significance can be reached, suggesting that the effect is large 
enough to be clinically relevant. 
 
These patients all underwent lumpectomy surgery in the Northern Sydney Central Coast 
catchment area in both public and private institutions and their radiotherapy was carried out 
at The Northern Sydney Cancer Centre (Royal North Shore Hospital), Australia. Four 
surgical clips were placed around the tumour bed as follows: medial, lateral, superior and 
inferior and one clip was fixed deep to the pectoral fascia. These clips were used to aid in 
accurate consistent CTV delineation (see Chapter 2). The 15 subjects undergoing 
chemotherapy (Chemo/RT) were scanned 2-3 weeks post-surgery. A second scan, which is 
normally the one that is used for radiotherapy planning, was taken at the completion of 
chemotherapy, approximately two weeks prior to the commencement of radiotherapy. This 
Chemo/RT cohort had a third scan during radiotherapy at 40 Gy, for a total of 3 CT scans. 
The radiotherapy alone (RT/alone) cohort had only 2 scans, the first 2-3 weeks post-surgery 
and the second taken during radiotherapy at 40 Gy, as per normal protocol (see study 
schema Figure 3.1). 
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Figure 3.1 Study Schema  
#Radiotherapy (RT), Chemo (Chemotherapy) 
Wks = weeks 
SURGICAL BED CLIPPING 
RT CT1 
2-3 wks post-surgery 
PRE-CHEMO CT1 
2-3 wks post-surgery 
CT2 POST CHEMO 
4-6 months post-surgery 
RT CT2 AT 40 Gy 
Approx. 9 weeks post-surgery 
RT/ Alone Cohort 1 Chemo/RT Cohort 2 
POST CHEMO CT3 AT 40 Gy 
Approx. 5-7 months post-surgery 
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3.2.2 Clinical target volume delineation and analysis 
Planning CTs were taken in the treatment position on a CIVCO Medical Solutions Posi 
board (Civco Medical Solutions, Orange City, Iowa, USA) inclined at a 5
0
 angle using a GE 
Lightspeed RT CT (GE Healthcare USA) with 3mm slice thickness. Scans encompassed the 
whole breast, extending superiorly to include the supra-clavicle margin. Standardised CTV 
delineation (see Chapter 2) was performed using 4-5 titanium clips placed at the extent of 
the tumour cavity and volumes were delineated by three trained (see Chapter 2) breast 
radiation oncologists (RO) using the Varian Eclipse planning system V10.  
The boost CTV was defined using the seroma where it was clearly visible, surgical 
information, and surgical clips. Seroma visibility was scored using the British Columbia 
Visualisation Score (Petersen et al., 2007) and where delineation was difficult to interpret, a 
second observer checked the contouring (see chapter 2).  
The RO outlined the boost CTV on each CT data set (see Figure 3.1 for the timing of these 
scans). An example of the delineated boost CTV for one subject is shown in Figure 3.2 
below. These volumes were completed at different time points but superimposed onto the 
last CT data set. The matching method used for CT fusion were bones, sternum, 
vertebrae ,and ribs as the primary match method with the patient’s breast contour and 
pectoralis clip as secondary matching tools. 
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Figure 3.2 Example Overlayed CTV 1, 2, 3 for Chemo/RT cohort  
CTV1 Pink, CTV 2 Green planning scan. CTV 3 Blue. at 40 Gy 
Each time a CT was acquired and delineated the volumetric size of the CTV in cm
3
 was 
measured and volumetric changes were recorded. Statistical analyses were carried out to 
quantify the CTV changes and to test whether patients undergoing chemotherapy had a 
different rate of CTV reduction compared to those having only radiotherapy post-surgery. 
The data was analysed using the statistical package STATA Version 11 (StataCorp LP). 
CTV size differences were compared between each CT time point within each cohort and 
between cohorts using the Wilcoxon rank sum test (significance value of p<0.05). It was 
hypothesised that there would be a significant rate of CTV change between CT1 and CT2 for 
each cohort but no significant rate of change between CT2 and CT3 for cohort 2. The 
Spearman Rho Coefficient was used to test the rates of CTV change (p< 0.05). 
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The correlation between initial CTV volumes for both groups and rate of CTV reduction was 
plotted against the subjects initial CTV to investigate if there is a relationship between CTV 
change and initial CTV post-surgery. 
3.3 Results 
3.3.1 Subject characteristics  
The subject characteristics are shown in Table 3.1. A total of 42 early stage breast 
radiotherapy participants were recruited. Of these, 27 were recruited into RT/alone (cohort 
1) and had surgery followed by radiotherapy. The remaining 15 subjects in Chemo/RT 
(cohort 2), had surgery, chemotherapy and then radiotherapy. The median days elapsed from 
surgery to the first CT scan for each cohort was 18 and 25 days respectively. The median 
time that elapsed between surgery to the second scan for the RT/alone cohort was 68 days 
while for the Chemo/RT cohort it was 126 days. Chemotherapy is delivered over 3-4 
months, hence the large time difference to the second scan for the two cohorts. The 
Chemo/RT cohort also had a third scan completed during radiotherapy, at 40 Gy, at a 
medium of 161 days post-surgery.  
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Table 3.1 Subject characteristics 
Subjects RT/ 
alone 
n=27 
Chemo/RT 
n=15 
 
Age at Surgery(years)   
 Median(SD) 58(8) 65(11) 
Tumour Stage   
 T-1 24 5 
 T-2 3 9 
 T-3 0 1 
N Stage 
 0 
 
24 
 
6 
 1 3 5 
 2 0 0 
 3 0 4 
Pathology Type   
 Infiltrating Ductal 20 15 
 Infiltrating Lobular 2 0 
 Ductal Carcinoma In situ 5 0 
Side   
 Left 12 9 
 Right 15 6 
Days from Surgery to CT1   
 Median 25 18 
 Range 10-37 10-28 
Days from Surgery to CT2   
 Median 68 126 
 Range 51-85 94-187 
Days from Surgery to CT3   
 Median n/a 161 
 Range n/a 137-228 
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A clip-based protocol had been implemented previously (see Chapter 2). This was shown to 
improve visibility of the CTV even in the absence of a seroma, and for this volume change 
investigation enabled consistent CTV delineation by the Radiation Oncologists. 
3.3.2 Elapsed time, dose and CTV changes 
The first CT performed for each cohort (CT1) was completed at similar median time points 
post-surgery (25 median days RT/alone and 18 days Chemo/RT cohort) with all subjects less 
than 5.3 weeks. There was no significant difference (p=0.08) between the initial mean CTV 
for each cohort: RT alone: mean 40 cm
3 
(SD 39), median 25 cm
3
 (range 6-186 cm
3
); and 
Chemo/RT: at 61 cm
3
 (SD 37), median 54 cm
3
 (range 4-118 cm
3
). The second CT scans 
(CT2) were completed at considerably different time points: median of 68 days for the 
RT/alone cohort and median of 126 days for the Chemo/RT cohort (See Table 3.1 and 
Figure 3.1). As indicated in Figure 3.1 both cohorts had a CT scan taken at 40 Gy. For the 
Chemo/RT cohort this was a third CT scan (CT3). 
There was no significant difference (p=0.89) between the CTVs for the two cohorts at 40 
Gy: RT/alone: mean 22 cm
3
 (SD 26), median 15 cm
3
 (range 2-121 cm
3
); Chemo/RT: mean 
20 cm
3
 (SD 25), median 14 cm
3
 (range 7-110 cm
3
). For the RT/ alone cohort, there was a 
significant reduction in CTV (p=0.01) from CT1: mean 40 cm
3
 (SD 39); to CT2 at 40 Gy: 
mean 22 cm
3
 (SD 26). This represents a mean volumetric change of 38.4% (see Table 3.2 
and Figure 3.3).  
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Figure 3.3 demonstrates that some patients in the RT/alone cohort had large volume 
reductions although most had relatively small changes. 
 
Figure 3.3 Change in volumes between CT1 and CT2 for the RT alone subjects 
 
Figure 3.4 demonstrates the volume reductions measured for each patient at each scanned 
time point for the Chemo/RT cohort. For the majority of patients there are large differences 
in the volumes measured between the first scan and the remaining two scans, with very little 
difference in the measured volumes between CT2 and CT3. Three patients at random time 
points had slightly larger CTV2 volumes measured than CTV1. Of these, patient 5 had a 
minor increase of 2 cm
3
 and patients 7 and 14 had post-operative complications resulting in 
swelling. Four patients had large volume reductions between CTV1 and CTV2. Of these, 
patients 1, 10 and 17 had large initial seromas (84 cm
3
, 123 cm
3
, and 186 cm
3
). Patient 20 
had an early CT at 12 days post-surgery so less wound healing was likely to have occurred. 
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Figure 3.4 Changes in volumes between CT1- CT2 and CT3 for the Chemo/RT 
subjects. 
 
In the Chemo/RT cohort, with an increased time delay of 4-6 months for chemotherapy, 
there was a significant reduction in volumes between CT1: mean 61 cm
3
 (SD 37) and CT2: 
mean 24 cm
3
, (SD 22), (p=0.01). There was no significant reduction in volume between 
CT2: mean 24 cm
3
 (SD 22) and CT3 at 40 Gy: mean 20 cm
3
 (SD 25), (p=0.89). Hence, with 
the chemotherapy related delay there is a significantly lower rate of change of CTV for the 
second phase of treatment with CT1-CT2 (43.6%) and CT2-CT3 (15.7%) (p=0.019) (see 
Table 3.2).  
.  
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Table 3.2 Volumetric Change 
  Time elapsed from surgery to scan 
(days) 
Volumetric change cc (% change) Significance 
No of 
patients 
Mean  Median Range Mean Median Range  
Chemo/RT
#
, CT1 to CT2  15 132 126 94-187 36.9(43.6%) 29.6(64%) -14.3-94 
P = 0.019† Chemo/RT #, CT2 to CT3  
(at 40 Gy)  
15 174 161 137-228 3.6(15.7%) 1.0(7.5%) -18.2-40.3 
Chemo/RT 
#
, CT1 to CT3 
 (at 40 Gy) 
15 174 161 137-228 40.4(59%) 30.6(71.3%) -11.9-89.7 
P = 0.03† 
RT alone*, CT1 to CT2  
(at 40 Gy) 
27 66  68 51-85 17.1(38.4%) 8.1(41.2%) -18.2-10.6 
All subjects CT1 to CT2  
 
42 89 75 51-187 24.2(40.2%) 9.0(51.1%) -60.2-87.8 N/A 
* = Patients receiving RT alone 
#= Patients receiving chemotherapy followed by RT 
†= significant at the p<0.05 level 
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For the combined data of both groups (42 subjects) there was no significant correlation 
between initial volume and change of volume at CT2 (Spearman Rho Coefficient 0.09, p > 
0.05). Most subjects in each group had an initial CTV ≤ 50 cm3 and Figure 3.5 clearly shows 
the unpredictability of volume change for these patients. Of the 15 subjects with a CTV 
>50cm
3
, eleven (73%) had a volume reduction >50%. The pattern shown in Figure 3.5 
demonstrates that large volume changes would be expected for patients with an initial 
volume >50 cm
3
, but greater numbers of subjects would be required to verify the 
significance of this finding. 
 
Figure 3.5 Relationship between initial volume and volumetric reduction (combined 
groups) 
 
3.4 Discussion 
In radical radiotherapy for breast cancer, the presence of a changing CTV will have an 
impact on the accurate delivery of breast boost radiotherapy. Variability of the CTV is of 
even greater importance when using treatment techniques such as those that irradiate smaller 
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partial breast volumes or when using a simultaneous integrated boost (SIB) technique. As far 
as we are aware this is the first prospective volume change study which delineated the CTV 
using both seroma and surgical clips as standard practice for study patients. Two patients at 
the beginning of the study failed to have clips placed during surgery (chapter 2 pages 32). 
Their seroma scores at the time of the first scan and the ability of the RO to consistently 
delineate the CTV on successive CT scans were considered justification for inclusion in the 
volume data analysis. Some researchers have suggested that clips aid the RO in CTV 
delineation on CT. This is of particular importance for those patients who have undergone 
chemotherapy prior to irradiation where, due to the longer time delay to radiotherapy, the 
seroma becomes undetectable on CT. Patients undergoing chemotherapy have less favorable 
disease markers and often require more extensive surgery. This could explain why the 
subjects in Chemo/RT cohort had consistently larger CTVs recorded after just 2-3 weeks 
post-surgery compared to those only requiring radiotherapy, although these CTV values 
were not significantly different (p=0.08).  
Our newly implemented clip based tumour bed localisation procedure (see Chapter 2) has 
enabled the characterisation of volumetric changes of the post lumpectomy CTV. Similarly 
to other investigators, we found that breast CTVs can change dramatically with time from 
initial surgery (Hurkmans et al., 2009; Jacobson et al., 2006; Kader et al., 2008; Oh et al., 
2006; Prendergast et al., 2009; Tersteeg et al., 2009; T. I. J. Yang et al., 2010). However, we 
have also found that most CTV shrinkage (38.4%) occurs by a median of 68 days, as 
demonstrated by the RT/alone cohort. The Chemo/RT cohort with the large time period to 
CT (overall median 126 days), showed a decrease in the CTV volume of 43.6% (see Table 
3.2).  There is a significantly smaller reduction in volume (p=0.018) from CT2 to CT3 for 
the Chemo/RT group compared with CT1 to CT2 for this group, showing slower volume 
reduction with time from surgery. 
The significant reduction in volume for the Chemo/RT group at 40 Gy compared with the 
RT/alone group at 40 Gy (see Table 3.2) must relate either to the extra time delay 
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experienced or to the chemotherapy, or to a combination of the two. As both groups received 
the same radiation dose, no relationship can be deduced between radiation dose and CTV 
shrinkage.  
Strauss et al. (2010), for 29 patients who received chemotherapy before radiotherapy in spite 
of reporting larger lumpectomy specimens for chemotherapy patients, found consistently 
small (<10 cm
3
) volumes irradiated when radiotherapy was delayed for chemotherapy. He 
also suggested this was due to the increased time delay or perhaps the chemotherapy itself. 
Our findings with small numbers of 15 patients supports the time delay theory, suggesting 
that after 9 weeks post-surgery, with or without the addition of chemotherapy, small CTVs 
are more likely. Regardless of the size of the initial CTV, the rate of volume shrinkage was 
similar.  
Kim et al. (2008) demonstrated large outlined volumes initially as the seroma fills with fluid 
less than 2-4 weeks post-surgery, then dramatic shrinkage. Similarly, Yang (2010) and Kader 
(2008) discovered a significant linear regression between seroma volume and time interval 
after surgery up to and including 8 weeks, with no significant relationship after this time. We 
also found, for the RT/alone cohort, that when the CT is taken in the first 9 weeks after 
surgery large volume reductions are seen. It appears that as long as there is sufficient post-
surgical wound healing, the addition of chemotherapy does not produce significantly greater 
volume reductions. Assuming that stable small volumes are preferable for enabling 
consistent dose coverage, our research suggests that if volumes do not change significantly 
after 9 weeks post-surgery then there is little value in rescanning at 40 Gy for this group. 
Researchers suggest that time delay from surgery to radiotherapy should be as short as 
reasonably possible (Chen et al., 2008; Hébert-Croteau et al., 2004; Huang et al., 2003), with 
Stefoski et al (2004) reporting that surgery to radiotherapy intervals of greater than 9 weeks 
had a trend towards an increased relative risk of death . On the other hand, Borger et al. 
(1994) reported that for each increase in irradiated volume of 100 cm
3 
a fourfold increase in 
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risk of fibrosis was observed. Thus, in order to reduce the irradiated volume and keep it 
relatively stable for those patients having radiotherapy immediately after surgery, while 
allowing for planning time frames, the planning CT should be performed as late as possible 
post-surgery (approx. 6-7 weeks) and the patient should commence radiotherapy no later 
than 9 weeks post-surgery. This allows the CTV to be at its most stable for radiotherapy, but 
also provides adequate time to carry out the pre-treatment planning CT. In contrast, 
Arcangeli et al. (2006) reported that radiotherapy after chemotherapy for node negative 
patients could be delayed by up to 7 months. As our data indicates, planning CT scans 
performed after chemotherapy is in most cases sufficient to produce small stable CTVs. 
The introduction of a simultaneous integrated boost technique can be hampered by 
substantial reductions in CTVs. Alderstein et al. (2011) suggested rescanning during 
radiation treatment to adapt the treatment plan to these changing volumes. They concluded 
that patients with initial seromas ≥40 cm3 should be monitored and those patients who have a 
≥20 cm3 reduction in the first four weeks should be rescanned. In our study, 11 subjects who 
had initial volumes ≥50 cm3 at CT1 had large volume reductions recorded at their subsequent 
CT2 scan.  The pattern shown in Figure 3.5 demonstrates that for those with initial volume 
≥50 cm3 rescanning is recommended as large volume changes for these would be expected. 
However, increased numbers of subjects would be required to verify this significance. 
All our subjects who were scanned between 7-9 weeks (CT2) post-surgery had volumes ≤30 
cm
3
. Hurkmans et al. (2012) designed and tested an adaptive radiotherapy technique 
requiring only those patients to be rescanned for planning who had volumes ≥30 cm3 and /or 
those whose initial scan was performed ≤30 days post-surgery. Based on their criteria, with a 
large sample size of 1274 patients, only 9% of patients needed a second CT scan. Using 
Hurkman’s criteria very few of our patients would have required replanning.  
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We therefore recommend that patients having radiotherapy post-surgery receive their 
planning CT as late as possible while still ensuring they commence treatment by 9 weeks 
following surgery. 
3.5 Conclusion 
This research has demonstrated that following surgery, patients receiving chemotherapy and 
or radiotherapy experience significant breast boost CTV reductions post-surgery and during 
radiotherapy. It appears that volume reduction has little relationship to either radiotherapy or 
chemotherapy, and is more a result of time given for post-surgical healing. CTVs for both 
groups become relatively stable after 9 weeks post-surgery. Due to planning time frame 
constraints, planning CT scans should therefore be performed between 6-7 weeks after 
surgery, allowing treatment to commence within the next several weeks. When introducing 
treatment techniques that particularly require stable CTVs (SIB, APBI) a second CT should 
be performed for patients whose initial CTV is ≥50 cm3, as large volume reductions for this 
group could be expected.  
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CHAPTER 4.  
The Role of On Board KV Imaging and kV Cone-beam CT for 
Treatment Verification and Guided Radiation Therapy of the 
Breast: A Systematic Review  
4.1 Introduction 
Breast cancer is the second most common form of cancer affecting women internationally, 
accounting for 15.3% of cancer related deaths in 2006 (Yarnold, 2009). As radiotherapy is an 
important treatment option, accurate treatment delivery is essential to deliver the required 
dose and improving treatment targeting and delivery may facilitate dose escalation. Many 
factors need to be considered to ensure accurate localisation of the treatment area. These 
factors include: patient stability, positioning, breathing motion, and contour changes of the 
breast. Factors that influence the ability to visualise clinical target volumes (CTVs) are 
image quality and/or whether three dimensional (3D) or two dimensional (2D) images are 
required. Orthogonal 2D kilovoltage (kV) images allow isocentre verification, but 3D images 
such as those produced by Cone Beam Computer Tomography (CBCT) enable internal 
structures and external patient contours to be visualised.  
Image guided radiotherapy (IGRT) can be used daily to improve localisation, patient 
positioning and external beam alignment in radiotherapy, allowing online matching and 
adjustments to a tolerance of 0 mm. IGRT can use several different imaging modalities 
including optical tracking methods (Bert et al., 2006; Chang et al., 2012), ultrasound 
(Chadha, Young, Geraghty, Masino, & Harrison, 2011; Smitt, Birdwell, & Goffinet, 2001), 
kV CBCT or megavoltage (MV) CBCT (Pouliot et al., 2005). kV CBCT has been 
successfully implemented for clinical use, for tumour sites such as prostate and lung (Jaffray, 
Siewerdsen, Wong, & Martinez, 2002; Purdie et al., 2007; Smitsmans et al., 2005), but has 
been slow in being implemented widely for breast radiotherapy treatment verification. 
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IGRT has the potential to facilitate planning target margin reductions. Target volumes for 
treatment are produced by definition of the CTV by the radiation oncologist at the time of 
planning CT, where treatment margins are added around the CTV to produce a planning 
target volume (PTV). This margin accounts for set up uncertainty and can be potentially 
reduced by using on treatment IGRT correction protocols. 
For many years whole breast irradiation (WBI) following breast conserving surgery has been 
delivered to reduce the risk of recurrence in the affected breast (Clark et al., 1996; Fisher et 
al., 2002). An additional boost to the tumour bed achieves a further decrease in local 
recurrence (Bartelink et al., 2001; Romestaing et al., 1997). Over the last decade there have 
been a number of advances in treatment delivery using techniques such as intensity 
modulated radiotherapy (IMRT), partial breast irradiation (PBI), and accelerated partial 
breast irradiation (APBI). IMRT has demonstrated reductions in radiotherapy side effects 
and improvements in dose uniformity for breast cancer patients (Harsolia et al., 2007; Vicini 
et al., 2002). PBI is a radiotherapy technique that localises treatment to the tumour bed and 
treats only a small volume. APBI is also being investigated (Smith et al., 2009) , and is a 
technique that has the advantage of not only reducing dose to the entire breast but also 
decreasing fractionated delivery regimes for patients.  
For many years setup verification for breast cancer treatment has involved tangential 
electronic portal images (EPIs) that are routinely compared to digitally reconstructed 
radiographs (DRRs) (van der Laan et al., 2010). Relying on bony anatomy as a surrogate for 
breast location, setup errors using a 5 mm tolerance protocol have been measured with this 
MV verification method (Michalski, Atyeo, Cox, & Rinks, 2012). Michalski et al., (2012) 
suggested that due to large maximum systematic inter- and intra-fraction variations observed 
in individual patients, there is a need for daily imaging before introducing modulated 
techniques and partial breast irradiation. kV imaging is now being used to minimize the 
effect of inter-fraction motion through daily analysis of images and immediate online 
correction protocols to correct set-up error. The major advantages of kV based imaging 
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protocols over EPIDs are improvements in image quality and contrast, along with reduced 
radiation dose (Lawson et al., 2008). This technology has been widely accepted as a tool to 
reduce setup errors and improve tumour site localisation for many tumours (Jaffray, 2007). 
The kV imaging technology consists of an X-ray tube mounted orthogonally to the treatment 
beam with a detector mounted on the other side. This On Board Imaging (OBI) device has 
the advantage of being able to rotate around the patient to produce a 3D CBCT rather than a 
2D representation of a patient’s anatomy. kV CBCT has become the imaging device of 
choice for many tumour sites (Lawson et al., 2008), but literature is scarce on using kV 
orthogonal or kV CBCT imaging for early stage breast cancer radiotherapy.  
There are many methods of measuring the accuracy of breast cancer radiotherapy treatment. 
On treatment imaging methods include: utilising skin marks, bone, soft tissue matching and 
radiographic markers such as surgical clips. Skin marks are variable daily and therefore not 
very accurate. Image matching using bones has greater stability than skin and has good 
contrast on kV imaging modalities, but assumes a constant relationship between the breast 
PTV and the underlying bones. However, perhaps for the most reliable verification method 
of the tumour bed for breast RT would be to use a combination of tumour surrogates: the 
surgical lumpectomy cavity (a fluid filled post-surgical cavity known as the seroma) and 
surgical clips (placed around this cavity). Recently Yang T.I. et al. (2010) verified that the 
seroma could be visualised on kV CBCT and thus has the potential to be used for IGRT.  
There are several challenges for users of kV imaging and particularly kV CBCT for breast 
radiotherapy. The breast is a mobile structure and the arm position of patients can be difficult 
to reproduce, so different immobilisation devices have been used to increase patient comfort 
and stability (Mitine et al., 1991; Nalder, Bidmead, Mubata, Tait, & Beardmore, 2001; 
Thilmann et al., 1998). Extension of the patient’s arms, laterality of the breast treatment 
region and stabilisation devices all pose a collision risk between the gantry and the patient. 
Small fields of view are often produced when using kV CBCT which can decrease image 
quality. Radiation dose must also be kept to a minimum during kV CBCT because of the 
 58 
 
secondary risk of cancers induced at low levels of radiation dose (Preston et al., 2002). This 
is particularly important for breast cancer patients, as the previously used tangential EPI’s 
did not irradiate the contralateral breast.  
Both 2D and 3D images are produced for EBRT on a linear accelerator using an OBI. The 
OBI extends from either side of the linear accelerator treatment head (at an angle of 90◦) and 
consists of a kV X ray tube and detector. The linear accelerator can rotate from -180◦ to 
+180◦ to produce both planar kV images and kV CBCT. The OBI produces the X-rays to 
enable on treatment breast position verification and image guidance for the treatment of early 
stage breast cancer. See Figure 4.1 below. 
 
Figure 4.1 Varian Linear Accelerator with On Board Imaging (OBI) arms parallel 
extending from the gantry of the machine. © 1999-2013 Varian Medical Systems, Inc 
 
In this review, kV imaging of the breast is discussed in terms of its ability to produce good 
quality 2D and 3D CBCT images. The acquisition of the images also relies upon the 
equipment being free of collision risk and the registration of these images needs to be quick 
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and accurate. This review will evaluate research using both kV orthogonal and kV CBCT 
images to verify treatment setup errors. As discussed in chapter 2, surgical clips and gold 
seed fiducials are frequently present in the tumour bed to ensure accurate CTV visualisation, 
so it is important to discuss the use of kV imaging to visualise these tumour surrogates. This 
information will inform radiotherapy departments’ decisions to implement new complex 
treatment verification techniques for breast cancer patients. This systematic review aims to 
collate literature available on the use of 2D and 3D kV imaging using an OBI and to define 
how different kV imaging can be used to verify breast radiotherapy.  
4.2 Methodology  
The methodology for this review was based on the Cochrane Handbook of Systematic 
Reviews of Interventions (Higgins, 2009). A systematic search of the literature was 
conducted using Medline, Cinhal, Embase, Scopus and Web of Science. Studies had to be 
published after 1990 and prior to December 2012 and were limited to women having radical 
radiation therapy to the breast in the supine or prone position using tangential or intensity 
modulated radiotherapy techniques. Studies needed to have described the effectiveness of the 
use of kV imaging and/or kV CBCT, in terms of measuring reproducibility (the ability to 
accurately treat the patient over successive fractions) and treatment verification (ensuring 
that daily treatment is delivered to the prescribed location). In this review articles on kV 
imaging of the breast are grouped into tables in terms of image quality, setup error and kV 
imaging using tumour surrogates.  
Inclusion criteria are listed in table 4.1. Studies needed to describe (in addition to inclusion 
categories found in Table 4.1) the method of on treatment field verification using Image 
Guided Radiotherapy techniques for breast cancer treatment using kV Imaging devices with 
or without the use of commercially available fiducial markers. 
Studies were excluded if they used optical guidance systems, kV cone-beam tomosynthesis, 
kV imagers on rails and the helical tomotherapy solution MVCT. This systematic review 
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only reviews kV imaging using commercially available kV OBI integrated systems which 
are readily available to most radiotherapy departments within Australia. Studies using MV 
imaging devices such as electronic portal imaging devices (EPID) were also excluded as they 
do not allow the same image quality as that of kV imaging and the production of good 
quality 3D CBCT images. Phantom studies investigating the use and visualisation of clips 
using kV imaging are described, these are articles discussing image quality and dose.  
Table 4.1 Criteria for selecting studies in this review 
Types of Studies English Language 
Human and phantom studies 
Tangential, IMRT and/or APBI techniques 
Published articles in peer reviewed journals 
Departmental QA  
Types of 
Participants 
Females undergoing treatment for breast cancer with 
radical intent 
Breast or chest wall irradiation  
Method of 
treatment 
verification 
kV imaging devices with or without fiducial markers. 
Types of 
outcomes 
Evidence available to inform the implementation of an 
expert IGRT protocol for breast radiotherapy. 
 
4.2.1 Search strategy 
A literature search was conducted from November 2010 to December 2012  using Medline, 
Cinhal, Embase, Scopus and Web of Science databases using the keywords listed in table 
4.2. A total of 120 articles were identified and exported into Endnote™, a bibliographical 
software package used to manage the search results. 
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After duplicates were removed, articles were excluded based on their title and abstract 
review (using exclusion criteria as previously described). The full text of the remaining 
articles was reviewed and reference lists were hand searched for any other relevant articles. 
Replication of the search criteria was carried out by a second researcher (JC) to ensure 
inclusion of all relevant articles.  
Table 4.2 Keyword search 
Terms related to on-treatment localisation or verification 
of radiotherapy in breast cancer using on- board kV 
imaging. 
1. Breast Cancer. 
2. Radiation Therapy. 
3. Radiotherapy. 
4. 1 and 2 or 1 and 3. 
5. image- guided radiotherapy. 
6. kV imaging. 
7. cone-beam CT. 
 
4.2.2 Analysis 
Articles that were included were placed into tabular form and analysed. This analysis was 
descriptive and where possible outcome measures were presented. Some articles had fewer 
than 10 subject data sets and were included in the study for completeness of the systematic 
review; however they are unlikely to be statistically valid. No two articles that were included 
measured the same parameters, so a meta-analysis could not be performed. 
4.2.3 Definition of Terms 
The term set up error in this document refers to the discrepancy between what is intended to 
be treated and the actual treatment position. Radiotherapy treatment set up errors can be 
random and systematic. Systematic error is an error that occurs with similar magnitude and 
direction on a regular basis. Systematic error may be due to such factors as the patient 
 62 
 
relaxing as treatment progresses, incorrect set-up instructions and equipment inaccuracies, 
while random error is less predictable. The individual systematic error for an individual 
patient is the mean error over a course of treatment. Population systematic errors are reported 
as an indication of a spread of individual means with an average standard deviation. Random 
errors can occur anytime throughout the course of treatment and can vary each day in 
direction and magnitude (Van Herk, 2004). Random errors can be introduced by such factors 
as the introduction of a new patient stabilisation device and variable patient compliance. 
Setup error measured by a single image will have both a random and systematic component. 
Inter fractional errors assess the correct patient setup with respect to the desired reference 
image from one fraction to the next and have both systematic and random components. Intra 
fraction movement is measured within one fraction of treatment. This movement may occur 
throughout the delivery of a single exposure or at any time during the delivery of a single 
treatment and is measured using displacements of the landmarks on the images recorded at 
certain intervals during the treatment fraction compared with the original CT image. This is 
often known as “real time imaging”. Only one article within this review reports intra fraction 
motion by comparing one matching method (bones) to another using gold seeds at a single 
time point during the treatment fraction (see table 4.3).  
Systematic inter fraction error is the average variation in treatment position for a particular 
patient, calculated from all treatment verification images compared to their reference image, 
which is the planning CT (Hurkmans, Remeijer, Lebesque, & Mijnheer, 2001). The mean 
systematic error refers to the average error of all patients in a given study. Some authors 
define residual error as the error that remains once all corrections have been applied. 
Michalski et al. (2012) discussed the variety of ways of reporting errors and decided to use 
the term ‘average movement’ to describe error across a course of treatment.  
Due to the great variability of reporting with small sample sizes and few similar studies to 
enable data pooling, this review has reported the studies in a tabulated descriptive manner. 
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4.3 Results 
Of 120 articles that were originally identified (see Figure 4.2), 13 proceeded to full review. 
These articles are discussed in terms of themes related to kV imaging for breast cancer 
patients. Table 4.3 presents a summary of studies that have used kV imaging for determining 
setup accuracy and Table 4.4 summarises studies that used surrogates for on-treatment 
tumour bed localisation. Four studies that relate to image quality/ phantom studies or the use 
of clips for treatment verification are discussed in the text. Table 4.5 presents studies that 
relate to possible implementation issues for kV imaging or kV CBCT. 
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Figure 4.2 Results of Research Strategy 
 
Most breast studies using kV imaging had small sample sizes of fewer than 25 subjects, 
making their data difficult to interpret. Table 4.3 shows six studies where random and 
systematic errors of inter fraction motion have been reported, in three descriptive and three 
comparative studies.  
Jain et al. (2009), White et al. (2007) and Lawson et al. (2008) described the role of kV 
imaging in the measurement of inter fraction motion during breast radiotherapy. All studies 
except Lawson et al. (2008) used kV CBCT imaging as an assessment tool. Lawson et al. 
(2008) used automatic co registration methods with kV orthogonal imaging and performed 
daily setup corrections using bony anatomy matched back to digitally reconstructed 
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radiographs (DRRs). White et al. (2007) followed up with a second kV CBCT after 
correction of patient localisation, to calculate ‘residual error’. All authors concluded that kV 
CBCT was no less accurate than EPIs or kV planar imaging, and that these were acceptable 
for routine use. White et al. (2007) assessed the role of kV CBCT for conventional skin mark 
setup error (Table 4.3) and determined there was good visibility of post-lumpectomy 
seromas. It must be noted that kV CBCT shifts were only actioned when a >3 mm shift was 
detected (White et al., 2007).  
All authors reported errors for individual points, such as bony landmarks or fiducial markers, 
while kV CBCT offers the ability to visualise the structure as a 3D soft-tissue structure. This 
was recognised by White et al., (2007), Yue et al., (2011), Fatanuse et al., (2008) and 
Topolnjak et al., (2010), who found substantial differences between matching points and 
localisation with CBCT. Yue et al. (2011) reported intra fraction motion by comparing gold 
seed matching to that of bony anatomy. Although variations were noted in the magnitude of 
set up error kV CBCT appears useful for clinical subsets of patients, for those with large 
breasts or anatomical variations during treatment. Both White et al. (2007) and Fatanuse et 
al. (2008) reported doses of approximately 3c Gy per kV CBCT. 
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Table 4.3 kV imaging errors in breast cancer patients  
Author Sample size Purpose Results (mm) 
Jain et al. 
(2009)  
10 Assess CBCT for inter fraction motion and dose homogeneity  
Match method skin and bones 
- descriptive 
5.9(SD 3.9) Lat 
2.3(SD 3.2 LG 
2.8(SD 3.5) Vert 
White et al. 
(2007) 
20 CBCT for setup error and soft tissue matching  
Assessed the setup error based on conventional skin marks. - descriptive 
 
Systematic errors detected using CBCT 
2.7 Lat, 2.4 LG 1.7 Vert 
Random Errors 
1.5 Lat,1.5 LG,1.6 Vert 
Lawson et al. 
(2008) 
25 Clinical experience with kV imaging for inter fraction motion - descriptive Range of Shifts 
-2.0 to +2.2 Lat 
-1.9 to +4.3 LG 
-1.8 to +2.0 Vert 
Yue et al. 
(2011) 
21 CBCT comparison of matches using bony landmarks versus gold fiducials Intra fraction motion detection 
4.2 (SD2.3) fiducials 
2.5 (SD2.6) bony matching 
Fatunase et al. 
(2008) 
10 Comparing 2-D kV/Mv registration to CBCT - comparison Residual error: 
+3.0 Lat 
+4.0 Long 
+4.0 Vert 
Topolnjak et 
al. (2010) 
20 Quantify setup errors 
CBCT Vs EPID (bones matching)- comparison 
EPID underestimates setup error 20-50% 
of the time. 
*Standard Deviation (SD) 
@ Lat (lateral),LG(longitudinal) and Vertical (Vert) 
# Magnitude of Average movement  
+ residual error (translational shifts after aligning the CBCT with the planning CT in the three major axis) 
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An Australian group which has published in this field, Willis et al. (2011) designed a kV 
non-orthogonal imaging system to verify APBI by matching surgical clips back to the 
original DRRs. If fewer than 4 clips were available, ribs were also used to aid in matching. 
After assessing their protocol, 17 patients were imaged using this system. The system was 
considered optimal in terms of image quality, clearance and dose. Surgical clips could be 
visualised and the images were performed at isocentre with minimal collision risk. Quick 
online automatic matching was reported, but additional training on the part of the treating 
Radiation therapist would be required to interpret these matched non orthogonal kV images.  
Penninkhof et al. (2012) described the practical use of the the ‘No action level’ (eNAL) 
setup correction protocol for 80 patients with surgical placed clips. An eNAL correction 
protocol requires the patient to be imaged for the first three fractions with an average 
correction measurement applied on the fourth fraction. This is then repeated weekly. As with 
Willis et al. (2011), two non-coplanar kV images were acquired and matched to the planning 
DRRs. The researchers reported that the application of an eNAL on clip matching resulted in 
improved setup accuracies for both tumour bed and whole breast treatments. 
Several authors discuss the use of CBCT in conjunction with soft tissue or clip based ‘on- 
treatment’ verification. Kim et al. (2007) presented an on-line verification procedure based 
on CBCT imaging of surgical clips for 10 patients in target based matching for APBI. 
Initially the patients were setup to lasers and skin marks, and then the first CBCT was taken 
and matched to clips on the planning CT. The second CBCT was completed and small 
residual errors were reported; thus CBCT matching using clips was feasible in reference to 
equipment, time and process. Table 4.4 reports the average magnitude of corrections and the 
residual errors detected using CBCT clip based matching. Donovan et al. (2012) assessed a 
CBCT treatment verification protocol on 38 surgically clipped breast boost patients. Yang et 
al., in 2010, investigated the use of CBCT for the monitoring of seroma reduction, the 
importance of which has been discussed as part of Chapter 4 of this thesis.  
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Table 4.4 The use of CBCT with or without Tumour surrogates  
Author Purpose Results (mm) 
Kim et al. (2007)  Using clips located on CBCT 
with the potential to decrease 
margins. The treatment couch is 
translated according to the shift in 
the clips' centre of mass between 
the planning CT and CBCT 
Average magnitude of clip 
based translocations was 7mm 
(SD2) 
Residual error magnitude  
1.6mm (SD1.3) 
Yang et al. (2010)  Comparing the use of CBCT to 
planning CT in reference to 
voluming. 
Voluming agreement between 
CBCT and Planning CTs. 
Donovan. (2012) Assessed the implementation of 
CBCT for treatment verification 
breast boosts. 
Systematic error was reduced 
from 3mm to 1.5 mm using a 
eNAL correction protocol. 
  
The image quality of kV CBCT and kV orthogonal OBI was addressed by two groups. 
McBain et al., (2006) investigated the image quality of kV CBCT for 10 different sites and 
reported on the images taken for three breast cancer patients, stating that these produced 
clear resolution images approaching that of planning CTs. A phantom study by Ueltzhoffer 
et al. (2010) was used to analyse the image quality produced by the Varian OBI V1.4. They 
reported that acceptable image quality was produced by decreasing the mAs, with doses 
measured as low as 0.02 -1.6 cGy (full fan mode) and 0.6 -3.2 cGy (half-fan mode).  
The remaining two studies by Thomas et al. (2009) and Buehler et al. (2009), identify the 
types of surgical clips that can be used for clip based online treatment verification using kV 
imaging. These authors found that medium titanium clips were affordable but can only be 
clearly visualised 55% of the time, while small tantalum clips are clearly visible 90% of the 
time but are three times the price. Buehler et al. (2009) reported difficulties visualising clips 
on orthogonal radiographs and recommended the use of CBCT to decrease artefacts.  
In spite of the advantages of the improved image quality of orthogonal kV imaging and the 
3D visualisation of soft tissue using kV CBCT, there have been challenges in the 
implementation of kV imaging for the breast. Some issues that require consideration when 
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implementing a kV based imaging protocol for the breast include: the dose delivered to the 
patient, the risk of equipment collision and the ease of accurate image co registration. A 
section of Table 4.5 reports whether authors have discussed any of these implementation 
issues. As discussed in Chapter 3, the size and shape of CTVs change over a course of 
treatment and these changes can be monitored using kV CBCT. Hence routine CBCTs 
performed as part of the treatment imaging protocol reduce the need to rescan the patient 
using a diagnostic quality planning CT. 
.
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Table 4.5 Articles that discuss doses, anatomy matching methods and seroma visualisation 
KV imaging 
Method 
Author Matched Method 
Sample 
Size>20  
Seroma 
Visible 
Surgical 
clips 
Auto co- 
registration 
Reported 
imaging dose to 
patient. 
Safe to acquire 
at iso centre 
CBCT 
Jain et al.(2009) 
Bones No No No Yes Yes No 
White et al. 
(2007) 
Lung/external 
contour 
Yes Yes No Potential Yes Yes 
Kim et al. 
(2007) 
Clips No Yes Yes Yes Yes No 
Topolnjak et al. 
(2010) 
Sternum/ribs Yes Unknown No Yes No Unknown 
Yang et 
al.(2010) 
Unknown No Yes No Yes Yes Unknown 
Donovan et 
al.(2012) 
Clips Yes Yes Yes Yes Yes Yes 
kV*  Yue et al. 
(2011) 
Bony to gold 
fiducials 
Yes Yes Yes Unknown No Unknown 
Lawson et al. 
(2008) 
Bony Yes Unknown Yes No Yes Unknown 
kV* vs. CBCT Fatunase et al. 
(2008) 
Bones, then soft 
tissue 
No Yes Yes No Yes No for both. 
 
*orthogonal kV imaging 
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4.4 Discussion 
This review describes how in room kV imaging systems have been introduced to improve 
treatment verification and treatment guidance for breast radiotherapy. Orthogonal EPIs (MV 
imaging) have been used for many years to verify a patient’s daily course of treatment, with 
setup errors measured consistently to a value of 5 mm (Michalski et al., 2012). However 
with the introduction of treatment techniques such as SIB,IMRT and APBI, as well as 
changing CTVs, volumetric daily kV imaging becomes more important. kV imaging with its 
increased contrast and 3D capabilities is the preferred imaging method when implementing 
IGRT of the breast.  
4.4.1 Selection of kV imaging method 
When using on board kV imaging, a decision must be made to determine the purpose of this 
type of imager. An EPID enables field boundaries and the amount of lung to be detected 
within the field while the patient is being treated and is suitable for tangential beam field 
arrangements. However, in the case of the beamlet delivery technique that is used for IMRT, 
verification of the treatment field boundaries is no longer possible. kV imaging and kV 
CBCT allow verification of the isocentre and in the case of kV CBCT, internal soft tissue 
anatomy visualisation. kV CBCT is also useful for PTV localisation for APBI, as the target 
will not necessarily be close to the bony anatomy in the chest wall, making localisation with 
EPI difficult. Surgical tumour bed clips are difficult to visualise on EPI imaging. However 
both Peninkhof et al.(2012) using kV non-orthogonal verification images and Donovan et al. 
(2012) using CBCT reported that kV visualisation of surgical clips could be routinely used 
to verify the whole breast and tumour bed for treatment. As discussed in Chapter 3, CTV can 
vary in size and shape from the beginning of radiotherapy to the end. Monitoring changing 
CTVs, as described by Yang et al. (2010), can be achieved with kV CBCT instead of 
requiring a patient reaching mid treatment to have a new planning CT. 
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4.4.2 Collision risks 
The addition of the source detector arms (OBI arms) for kV CBCT poses collision risks with 
the patient who is lying supine on a slightly inclined board. The non-central location of the 
isocentre makes clearance with the linear accelerator even more problematic (Fatunase et al., 
2008). The potential collision risk when imaging the breast might be one reason for the slow 
rate of uptake of this imaging modality by the general radiotherapy community. One way of 
overcoming this collision risk was explored by Willis et al. (2011) who used non coplanar 
kV images, but this technique does not provide 3D soft tissue visualisation of internal 
structures. One clinical issue that is under investigation is adapting the CTV margins in 
response to shrinking or growing tumours using kV CBCT imaging protocols, enabling soft 
tissue monitoring (Hurkmans et al., 2012). Such ART procedures would not be able to be 
initiated using the non-coplanar kV imaging as discussed by Willis et al. (2011). In contrast, 
Donovan et al. (2012) overcame collision risks by pre defining simple constraints, by 
obtaining a single image and a treatment isocentre that was <8 cm from midline and a 
isocentre-couch distance <30cm. 
The need to visualise internal structures for the use of APBI/ SIB or the need to monitor 
seroma changes might far outweigh the collision risks with OBI kV imagers. When the 
possibility of a geographic miss of the target is high as might be in the case for APBI, or in 
the case of changing CTVs (Chapter 3), the issues of the risk of collision with equipment 
must be overcome. To prevent the possibility of machine and patient collisions, breast kV 
CBCTs will usually not be acquired at the treatment isocentre but off-centre. Once the image 
has been acquired the patient is moved either manually or automatically back to the 
treatment isocentre before the correction shift is applied (Fatunase et al., 2008; Jain et al., 
2009b; Kim et al., 2007). This process, whether manual or automatic, adds time and 
potential errors to the treatment verification process. The kV OBI detector field of view 
(FOV) for kV CBCT is limited in both the longitudinal and lateral directions. One way of 
overcoming a limited FOV when using kV orthogonal images is by displacing the detector 
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to visualise specific anatomical structures. In the case of kV CBCT by placing a half bow-tie 
filter into the OBI detector mount an increased FOV is achieved in the longitudinal direction 
(Lai et al., 2009). 
4.4.3 Image quality and contrast 
Image quality and contrast are better with kV orthogonal image detectors than with MV EPI 
devices (Lawson et al., 2008). For kV CBCT, the images are reconstructed in a 3D volume, 
and the image quality could be variable depending on different reconstruction algorithms 
and the geometric setup and choices of beam parameters. Ueltzhoffer et al.(2010) and 
McBain (2006) describe clear image resolution when using kV imaging modalities, but they 
both suggest the need for organ specific sparing.  
4.4.4 Imaging and dose 
There is a wide variety of other imaging systems that can be used for IGRT of the breast. 
These include 3D ultrasound image guidance (Leonard et al., 1993) and optical tracking 
systems (Baroni et al., 2003; Bert et al., 2006; Chang et al., 2012; Miller, 2008). However, 
kV imaging is often the imaging modality of choice as the OBI kV imager is widely 
accessible and considered accurate as an imaging modality. There is a secondary risk of 
cancer at low dose radiation levels and care must be taken when introducing imaging dose 
(Preston et al., 2002). There is limited literature related to radiation exposure to breast cancer 
patients (Kan, Leung, Wong, & Lam, 2008), however, in the case of kV CBCT, the 
contralateral breast now receives increased doses and in the case of IGRT this could 
potentially occur daily. White et al. (2007) and Fatunase et al. (2008) reported imaging doses 
of approximately 3cGy per image.  
Most recently Donovan et al., (2012) reported on the clinical implementation of CBCT for 
the verification of an SIB technique for breast patients. This patient cohort was treated on a 
Elekta linear accelerator and used kV CBCT IGRT to asses treatment verification The 
authors reported contralateral breast doses of approximately 2 mGy per scan (right breast) 
 74 
 
and 12m Gy (left breast).The differences in contralateral breast dose is due to gantry rotation 
restrictions where the left limits the contralateral breast dose . Donovan and colleagues 
report that the right breast protocol used in this study exposes both breasts. Similarly 
Ueltzhoffer et al. (2010) using the reduced-arc offset imaging protocol on a Varian linear 
accelerator reported doses of 7.2m Gy to the ipsilateral breast and 0.2m Gy to the 
contralateral breast. Ueletzhoffer et al. (2010) and McBain et al. (2006) suggest that a 
reduction of dose to the contralateral breast can be achieved by decreasing the mAs 
administered when taking a kV image. This has the potential to decrease image quality, but 
by selecting appropriate start and stop angles and adjusting the mAs accordingly, good 
image quality can still be achieved using kV CBCT. More work is required in the accurate 
reporting of imaging doses for breast radiotherapy using commercially available kV CBCT 
devices. 
4.4.5 Image registration 
Once good image quality is achieved, the method of image registration needs to be decided. 
Should bones, soft tissue or tumour bed surrogates be used? The method used will partly 
depend on the main reason for the imaging. As discussed previously, EPIDs are sufficient 
for whole breast radiotherapy verification, but the use of kV CBCT provides full volumetric 
information including path length, contour variation, internal anatomy and internal tumour 
location utilising clips.  
Lawson et al. (2008) demonstrated the use of daily kV imaging, matching bony anatomy 
back to planning digitally reconstructed radiographs (DRR’s). However Topalnjak et al. 
(2010) reported that EPIDs underestimate bony setup error and that CBCT has the added 
advantage of 3D soft tissue visualisation, and thus better co-registration. White et al. (2007) 
suggested that soft tissue CBCT co-registration was useful for large random errors for APBI.  
The CBCT protocol implemented by Donovan et al. (2012) specifies limits on the plan 
isocentre distance from midline that enabled the same isocentre to be used for planning and 
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imaging. They commented that it was unlikely all pairs of six clips would be matched at 
each session due to possible deformations in the excision cavity. The 95% isodose line in 
addition to the tumour bed PTV as structures on the reference images were also used as 
matching structures. 
4.4.6 Marker based matching and CTV monitoring 
The PTV for partial breast irradiation consists of the surgical cavity plus a margin, resulting 
in small field sizes for treatment. Due to the tight margins used, small changes in the tumour 
cavity size or inter or intra-fraction motion could potentially produce over or under dosing of 
breast tissue. Yue et al. (2011) postulated that the seroma / marker based treatment 
verification approach would improve treatment accuracy and enable IGRT. As markers are 
easily visualised using kV imaging and can be a surrogate for the tumour position, this 
technique would be a better verification tool than matching to skin or bones. By visualising 
breast soft tissue markers rather than matching to skin or bones, and matching daily to these, 
there should be fewer inter fraction variations across a course of treatment. Donovan et 
al.(2012) suggested when using a marker based CBCT verification protocol that boost 
treatment margins potentially could be reduced to a 5 mm setup error margin. 
Thomas et al. (2009) and Buehler et al. (2009)., identified appropriate tumour surrogate clips 
to be placed at the time of surgery. The location of these clips was not the focus of these 
papers, but it is clear that at least one clip was fixed to the underlying pectoralis muscle to 
ensure consistency among patients. The authors reported that surgical clips cannot be 
visualised using EPIDs and are also difficult at times to visualise on orthogonal kV images. 
This in part is due to imaging artefacts that can be produced due to bony structures such as 
the ribs lying close to the clips. In contrast, Willis et al. (2011) reported using non co planner 
kV imaging to visualise surgical clips and Penninkof et al.(2012) developed a treatment 
verification protocol utilising these clips that resulted in better setup accuracies for both the 
tumour bed and whole breast .Artefacts are also sometimes visualised from clips on kV 
CBCT; one solution to reduce these artefacts is to use incremental arc angles to produce the 
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kV CBCTs. Instead of matching directly to clips isodose lines can be transferred from the 
planning system to ensure clips are encompassed in the PTV. Donovan et al. (2012) 
imported the 95% isodose line from the planning system and ensured that this isodose line 
encompassed the clips. 
Kim et al. (2007) and Yang et al. (2010) discuss the use of kV imaging protocols to 
accurately deliver APBI which requires accurate tumour localisation as well as on-treatment 
seroma monitoring. These report that kV imaging that allows internal anatomy visualisation, 
with its increased image contrast enhancing abilities and CBCT capability, is an attractive 
option to visualise seroma changes over time. The ability to monitor seroma changes during 
treatment has the potential to allow consistent on-treatment tumour dose coverage through 
adaptive radiotherapy (ART) planning techniques. The potential to adapt the plan to these 
changing planning volumes suggests that treatment margins could be reduced during a 
course of treatment. Kim et al. (2007) utilised kV CBCT to visualise tumour markers (clips). 
This online imaging protocol combined with corrections for breathing (intra fraction 
motion), changes in tumour cavity and other sources of error, has the potential to reduce the 
CTV to PTV margin from 1 cm to potentially 6mm. 
The protocoled introduction of surgical clip insertion around the breast tumour bed cavity, 
described in Chapter 2, has led to the desire to use these clips for daily treatment 
verification. Hence this systematic review was used to assist development of a non-coplanar 
kV imaging protocol utilising surgical clips at the Northern Sydney Cancer Centre 
Department of Radiation Oncology. The implementation process of matching to surgical 
clips for boost irradiation utilising the new kV imaging method was under investigation  in 
April 2013. Ultimately it is intended to move towards CBCT verification for IMRT-SIB. 
4.5 Conclusion 
For robust radiotherapy techniques such as the traditional two field tangential technique, MV 
imaging with current CTV-PTV margins of 10mm is adequate. kV imaging has an 
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advantage over MV imaging of lowering radiation doses and thus should be the preferred 
method for IGRT. To ensure accurate treatment delivery, kV imaging of the breast is 
necessary because of its increased image contrast, better image quality, tumour surrogate 
visualisation (clips). For new complex treatment techniques such as IMRT, SIB and APBI, 
where volumetric information is required, kV CBCT should be used. Although there has 
been some research conducted using kV OBI devices for treatment verification and IGRT 
for breast radiotherapy, further research is required to investigate their uses for adaptive 
radiotherapy and margin reduction.  
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CHAPTER 5  
Discussion and Conclusion 
 
Patients who undergo breast conserving therapy (BCT) require multimodality treatment 
involving surgery followed by radiotherapy (RT), or a combination of surgery, 
chemotherapy and radiotherapy. After the completion of surgery there is an initial healing 
period that takes place prior to the commencement of radiotherapy planning. Accurate 
definition of the CTV is crucial so it can be treated when it is at its smallest and at its most 
stable post-surgery. The issues of CTV stability and changing size are of particular relevance 
for newer techniques involving small volumes, such as APBI or SIB. Older techniques also 
are risky when the tumour bed is boosted with inadequate knowledge of its size and location. 
There has been considerable material published since the commencement of this research 
that has investigated the size and shape changes of the breast boost CTV form surgery to the 
completion of radiotherapy. Much of this research relates to small changing CTVs and how 
these affect APBI or SIB treatment techniques. (Kim et al, 2010, Hurkmans et al, 2012). 
The CTV for breast RT has historically been delineated in many ways including: scar based, 
surgical reporting, ultrasound and with CT / seroma (see Chapter 1 page 9). Researchers, 
however, have reported the inaccuracies of using clinical delineation methods such as pre-
operative imaging, clinical palpation and the location of the surgical scar (Bedwinek, 1993; 
Denham et al., 1991; Harrington et al., 1996; Krawczyk & Engel, 1999; Machtay et al., 
1994). Many of these have also demonstrated considerable inter observer variability (Landis 
et al., 2007; Li et al., 2009).  
With the increased use of oncoplastic surgery, and when no seroma is present, surgical clips 
provide increased radiographic information that can be used by the RO for CTV delineation 
purposes. Surgical clip CTV delineation is recommended by surgeons in the UK protocol for 
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the IMPORT trial (Coles et al., 2009). The issues related to the use of surgical clip CTV 
localisation are discussed in chapter 2, page 33.  
The primary purpose of this research was to investigate the value of surgical clips in the 
breast cancer surgical tumour bed. This was done by (1) the introduction of an evidence-
based protocol for the insertion of clips and an evaluation of their effect on CTV delineation 
(Chapter 2 pp. 22 to 35), (2) the investigation of the characterisation of changing CTVs post-
surgery and during radiotherapy within two distinct cohorts was made possible by 
visualising the surgical clips (Chapter 3 pp. 37 to 54), and (3) evaluating the application of 
on-treatment kV imaging using surgical clips to delineate the CTV (Chapter 4 55 to 76).  
5.1 Introduction of surgical clip CTV delineation 
In 2010 the decision was made to improve breast boost localisation for radiotherapy in 
preparation to take part in international clinical trials at the Northern Sydney Cancer Centre 
Department of Radiation Oncology Royal North Shore Hospital (RNSH) .This procedure 
utilised radiopaque surgical clips placed around the tumour cavity using a standard surgical 
placement protocol. This tumour bed clipping protocol to be used for breast boost CTV 
delineation is the first developed and evaluated within the Australian context. The 
experience of the first 42 patients at RNSH from June 2010 to December 2011 inclusive was 
reported. 
The historical development of clip based CT/seroma localisation of the CTV is presented in 
Chapter 2 page 22. Weed (2004) and Coles (2009) had previously reported, when using 
serial CT, that clips were a stable representation of the post-surgical cavity. 
In order to improve CTV delineation of the surgical bed a small multidisciplinary team 
(MDT) investigated and assisted in the implementation of a surgical clip protocol for 
surgical bed delineation. A planning and implementation phase preceded placement of 
surgical clips around the tumour cavity. This was a prospective cohort study with patients 
stratified into one of two arms: those who went directly from surgery to radiotherapy and 
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those who had surgery, chemotherapy and then radiotherapy. At surgery, clips were placed 
around the tumour bed as follows: medial, lateral, superior and inferior. One clip each was 
also placed at the pectoral fascia and anteriorly, close to the suture line. The British Seroma 
Visualisation Scale (Petersen et al., 2007) was used to test the ease of delineating the CTV 
after clips had been inserted into the tumour cavity. For patients whose seroma score 
visualised on CT was was graded as ≤3 the clips were considered necessary to ensure 
consistent accurate CTV delineation. Seroma scores of ≥4 were easily identified on CT 
without the need for clips and thus the clips were considered to have provided no extra 
information, and did not improve delineation of the CTV. A satisfaction survey was used to 
gauge the acceptance of this new practice for both the surgeons and radiation oncologists. 
Coles et al. (2009) evaluated the use of medium titanium clips for tumour bed radiotherapy 
following BCS for 30 subjects. In contrast this study reported on the implications of 
introducing a clips based CTV protocol for 42 subjects (see page 31) and deliberately 
separated them into two cohorts: chemotherapy delayed radiotherapy (15 subjects) and those 
having radiotherapy soon after surgery (27) .The two cohorts were chosen as it was observed 
by the ROs that there were major difficulties in visualising the seroma on CT some 3-4 
months post-surgery. The fifteen patients whose radiotherapy was delayed due to 
chemotherapy had seroma scores ≤3 and it was difficult to see the seroma at all for many of 
these patients. Overall, the clips improved CTV delineation in 14 /15 Chemo/RT subjects 
(one patient was failed to be clipped) and in 20 /27 RT/ alone patients with one patient failed 
to be clipped (see page 32). As Coles et al. (2009) reported clip migration to be less than 
10% of cases (using a paired clip protocol) paired clips were not used in our study, which 
simplified the process. When surveyed, the surgeons found the procedure was simple to 
administer, and all radiation oncologists indicated that the clips aided in accurate CTV 
delineation for treatment planning purposes. Now the surgeons are accustomed to the 
procedure, compliance is expected to continue. 
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This research has successfully implemented a protocol based breast boost localisation 
procedure utilising titanium surgical clips which has improved boost CTV delineation for 
breast radiotherapy patients. RNSH patients will also be able to take part in breast 
radiotherapy clinical trials that require more complex localisation and treatment protocols. 
The ability to delineate the CTV even in the absence of seroma was crucial for the second 
study; enabling the consistent measurement of the CTV changes for patients over long 
periods of time (see Chapter 3).  
The ability to visualise these radiographic clips using the kV OBI capabilities is discussed in 
Chapter 4. The use of kV OBI allows 3D CBCT on board matching of surgical clips and a 
new treatment verification protocol will be developed to ensure consistent accurate treatment 
delivery.  
5.2 Dynamic CTVs and the timing of radiotherapy post- surgery  
The investigation of dynamic CTVs and the timing of radiotherapy planning post-surgery is 
the first of its kind within an Australian radiotherapy setting. The objective was to establish 
the best time to carry out CT planning for patients undergoing radiotherapy alone as well as 
those having radiotherapy delayed due to chemotherapy, in terms of stable CTV delineation 
for breast boost radiotherapy. 
Excision cavity volumes and tumour bed volumes were investigated by Oh et al (2006), 
Tersteeg et al. (2008) and Prendergast et al., (2009)., Hurkmans et al. (2009) compared 
visible boost volume changes as delineated by the RO, while Jacobson et al. (2006) in their 
study contoured what they called ‘lumpectomy cavities’. Strauss et al. (2010) recognized the 
shrinkage of volumes related to chemotherapy delayed radiotherapy patients. Terminology 
in the literature has been variable so in this work the important volume to be studied was the 
CTV, which is defined as the visible seroma plus clips as visualised on a radiotherapy 
planning CT. 
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A local standardised clip CTV delineation protocol was needed to ensure consistent CTV 
delineation and was implemented as part of this research (see Chapter 2). This process 
enable examination of the change in CTV over time, which was carried out on the same 
subject cohort as described in section 1.5 (15 Chemo/RT and 27 RT/ alone subjects). 
We found, similarly to many other researchers, (Oh et al., 2006, Strauss et al., 2010, 
Prendergast. 2009,  Tersteeg et al., 2009,  Jacobson et al., 2006 .and Yang et al., 2010) that 
the breast boost CTV changed significantly post-surgery and during radiotherapy and the 
initial defined CTV size is not a predictor of relative CTV reduction. Regardless of the 
addition of chemotherapy, significant volume reductions in both groups of patients occurred. 
There was a 38.4% reduction at mean 9 weeks for the RT group and 43.6% reduction to a 
mean CTV of 2.6cc at 40 Gy at 19 weeks for the Chemo/RT group (see Table 3.2 page 49). 
Due to planning time frame constraints, to allow treatment to commence within the next 
several weeks, planning CT scans should be completed between 6-7 weeks after surgery. 
The slower rate of volume reduction after 9 weeks post-surgery indicates that there is no 
need for an additional CT to be completed at 40 Gy except for those patients who have an 
initial CTV ≥50 cm3 (Figure 3.5 page 50). . 
The knowledge of CTV changes over time should inform the implementation of ART; APBI 
and SIB techniques for early stage radiotherapy (see Chapter 3 pp. 37 to 54). 
5.3 The use of kV on board Imaging for radiotherapy breast 
patients 
A thorough literature review was carried out into on board kV imaging for breast 
radiotherapy (Chapter 4). Recommendations about routine on treatment verification imaging 
can be made, based on the following factors: the purpose for kV imaging, collision risks, 
image quality/contrast, radiation dose, accurate registration methods, and marker based 
matching and CTV monitoring. As discussed in chapter 4 (pp. 63-76) for robust radiotherapy 
techniques such as the traditional two field tangential technique, MV imaging with current 
CTV-PTV margins of 10mm is adequate. When implementing complex treatment techniques 
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such as IMRT, APBI, photon beam boosts as well as changing clinical target volumes, 
volumetric daily kV imaging becomes more important.  
kV CBCT with the ability to visualise internal structures shows promise for routine use in 
the future. However, more research is still required investigating issues related to accurate 
soft tissue visualisation, organ motion, patient positioning and automatic co registration of 
images with or without radiographic tumour surrogates. 
5.4 Limitations 
Patients under 40 yrs. of age were not recruited for this research because of ethical 
requirements that all patients had to be over 40 yrs old or post-menopausal to receive one 
extra CT beyond clinical purposes. This limited the number of subjects that could be 
recruited over a reasonable period of time in a moderate sized department. Other authors 
have used similar or smaller numbers (Hurkmans et al., 2009; Jacobson et al., 2006; Oh et 
al., 2006; Prendergast et al., 2009; Tersteeg et al., 2009), while Kader et al. (2008) reported 
seroma reduction on larger numbers (77 participants).  
As far as the author is aware this is the first study to deliberately separate out those patients 
who underwent chemotherapy prior to radiotherapy.  The study protocol was designed to 
have matched numbers of 30 patients. However, in order to complete this project in a timely 
manner as part of candidature data collection was limited to a 14 month period. As 
chemotherapy alone has protracted time periods of up to 6 months post-surgery and the 
ethical eligibility restrictions of over 40 yrs / post-menopausal small subject numbers were 
thus recruited particularly for the chemotherapy cohort (15).  As with any statistical test even 
with small sample sizes significance can be reached suggesting that the effect is large 
enough to be clinically relevant. The restricted range of scanning time-points was due to a 
deliberate decision to keep the number of CT scans per subject to a minimum, in order to 
satisfy ethical requirements. The study protocol required patients to attend for planning CT’s 
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on multiple occasions. Patient appointment compliance and the use of specialist equipment 
such as the CT scanner contributed to the broader range of CT time points.  
Weed et al (2004) and Coles et al (2009) reported that clips were a good radiographic 
surrogate for the changing seroma with minimal clip migration. This was not verified in this 
study, as it was assumed that the clips placed would behave similarly to those observed by 
Weed and Coles.  
   
5.5 Recommendations 
1. A standardised medium titanium clip based CTV delineation protocol should be 
implemented as standard practice for all early stage breast cancer patients within the 
Australian setting. This should include a minimum of 4 clips placed around the tumour bed 
plus one fixed to the pectoralis muscle. 
2. Early stage breast cancer patients who require RT should have their planning CT 
scans performed at least 6 weeks post-surgery to minimise the need to rescan patients. 
3. When introducing treatment techniques that require stable CTVs (eg. SIB, APBI) a 
second CT is currently recommended for patients whose initial CTV is ≥50 cm3, as large 
volume reductions for this group are likely. The use of routine kV CBCT would remove the 
need for a second CT as volume changes would be continuously monitored. 
3. kV imaging protocols for breast radiotherapy should be implemented when using 
photon beam planning. This is particularly important for new complex treatment techniques 
such as IMRT, SIB and APBI. 
5.6 Future Research 
This research concentrated on the primary tumour bed volume with whole breast volumes 
not being investigated. Total breast volume changes during a course of radiotherapy as 
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compared to the breast boost CTV changes for complex planning techniques such as IMRT 
SIB warrant further investigation.  
The systematic review as presented in chapter 5 has been used to inform the development of 
a non-coplanar kV imaging protocol utilising surgical clips at the Northern Sydney Cancer 
Centre Department of Radiation Oncology. Implementation of matching to surgical clips for 
boost irradiation utilising a kV imaging method is currently under investigation.  
Once a kV CBCT treatment verification protocol utilising clips as the matching method is 
implemented, a more detailed representation of tumour bed shrinkage in the whole period 
from surgery to the completion of radiotherapy could be investigated. Routine CBCT will 
make this possible. This has the potential to facilitate the implementation of ART and 
possible margin reductions.  
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APPENDIX A  
Intra Operative Clip Placement 
 
Intra Operative Clip Placement – Breast boost Localisation using clips after breast 
conserving surgery: Changes in breast boost volumes from breast surgery to the 
completion of radiotherapy. 
Clip placement
Lateral Clip
Post Clip
Med Clip
CTV 
outlined
 
Clip 
Identifier 
Anatomical position of 
clips 
 O ‘clock  
position 
A Medial extent tumour bed    
B Lateral extent tumour bed   
C Superior extent tumour 
bed 
  
D Inferior extent  
Tumour bed 
  
E Anterior extent 
Tumour bed 
  
F Base of the Cavity and or 
fixed to the pectoralis 
fascia 
  
G Fixed to pectoralis fascia   
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